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Abstract of the Dissertation
Identify Genetic and Epigenetic Abnormalities Associated with Therapeutic Vulnerability in
Human Cancers
by
Wen-Wei Liang
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Genetics and Genomics
Washington University in St. Louis, 2021
Professor Li Ding, Chair

Human cancer is a complex and dynamic disease with mutational, spatial, and temporal
heterogeneity. There has been a concerted effort to address the heterogeneity by profiling largescale multiomic datasets with an emphasis on abnormalities such as DNA mutations at coding
regions and structural variants. However, a systematic analysis of alterations at “dark matter” is
lacking – including DNA slippage events at microsatellite sequences, gene fusions arising from
genomic rearrangements, and aberrant DNA methylations at promoter regions. This dissertation
focus on developing data-driven computational analysis pipelines to study the patterns of
microsatellite instability, gene fusions, and aberrant DNA methylation, and their functional
impacts within and across cancer types, utilizing integrative system-biology approach that
combines multi-dimensional genomic, epigenomic, proteomic and clinical data. First we estimated
the mutational load and microsatellite instability (MSI) status of 10,980 tumors across 33 cancer
types from The Cancer Genome Atlas (TCGA). Beyond the well-characterized canonical MSIprone tumor types, we identified additional MSI-high tumors in other non-canonical MSI tumor

ix

types and further validated in another independent data set from the Clinical Proteomic Tumor
Analysis Consortium (CPTAC). A survey of the 993 CPTAC tumors across 7 cancer types
revealed tumors with high MSI were associated with high number of predicted microsatellitederived neoantigen, suggesting that the aberrant expansion and deletion of microsatellite sequence
is immunogenic even the non-canonical MSI-high tumor. Next, we focuses on investigating gene
fusions in 9,624 TCGA tumor samples across 33 cancer types predicted by multiple RNAsequencing-based fusion calling tools and validated by orthogonal whole-genome sequencingbased approach. We demonstrated that gene fusions are mutually exclusive with the other driver
mutations in most of the cancer types, and function as the sole driver in more than 1% of cancer
cases. Lastly, we leveraged the complementary nature of RNA-seq and proteomic data to identify
aberrant DNA methylation leading to both transcriptional and translational changes. The integrated
multi-omic profiling cataloged epigenomic aberrations of 506 CPTAC tumors across five cancer
types, highlighting key changes to driver genes that affect cancer hallmark pathways in a
coordinated manner. Overall, our systematic pan-cancer studies uncover determinants and
consequences of genetic and epigenetic variation beyond the conventional mutational profiling,
revealing potential new disease mechanisms and therapeutic opportunities.
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Chapter 1: Introduction

1

Cancer is the second leading cause of deaths globally, nearly 1 in 6 deaths is due to cancer.
With decades effort in learning cancer genome, precious lessons from genome sequencing studies
shows that each cancer type has distinct mutation pattern and treatment responsiveness1,2. While
breathtaking “mountains”, such as recurrently mutated genes, has greatly advanced our knowledge
of human cancer, little is known about the “hidden hills” that are located outside of protein coding
regions3. New strategies for the prevention and control of cancer will rely on a thorough
understanding of the genetic factors both at the coding and noncoding regions in human genome.

1.1
Cancer is a heterogeneous and complex disease
driven by genetic mutation
Cancer cells are able to undergo unrestrained proliferation, invade surrounding tissue,
and metastasize to distant organs. The molecular mechanisms that underlie these characteristics of
cancer cells are the sustained proliferative signaling, evasion of growth suppressors, resistance to
cell death, replicative immortality, induction of angiogenesis, activation of invasion and metastasis,
reprogramming of energy metabolism, and evasion of immune destruction4. Generally, these
hallmarks of cancer cells are driven by genetic variation, which convert a normal cell to a benign
tumor, or a benign tumor to a malignant one.
In the process of tumor development, tumor cells undergo continual evolution to
establish malignancy. Various mutations are acquired and selected against during this process. The
mutations that confer a selective growth advantage to the tumor cell over other cells are driver
mutations, which are thought to have a causal role in cancer initiation and progression. On the
other hand, co-occurring mutations that do not affect the fitness of cancer cells are passenger
mutations, which are generated by chance, as a result of the constant background mutation rate3,5.
2

Cancer cells usually carry high numbers of passenger mutations during tumorigenesis because they
are neutral with respect to selection. Therefore, distinguishing driver mutations from commonly
abundant passenger mutations is critical for the understanding of tumor development6.
A typical solid tumor has been estimated to contain about 30 to 70 nonsynonymous
mutations that have accumulated during development, while it requires only 2 to 8 driver mutations
for tumorigenesis. Most of these driver mutations are found to either activate oncogenes or
inactivate tumor suppressor genes3. Oncogene activation or overexpression usually drives the
growth of the cell in which it resides. One prominent example of an oncogene in breast cancer is
human epidermal growth factor receptor 2 (HER2)7. It is a tyrosine kinase receptor that can
dimerize with itself or other membrane receptors. The dimerization/oligomerization of HER2
initiate various proliferation-promoting signaling pathways, including mitogen-activated protein
kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K) pathways. Gain-of-function
mutations in HER2 account for approximately 20% of breast cancer tumors. In addition, inhibition
of the aberrant or overabundant HER2 proteins is able to reverse the oncogenic effect of HER2,
which makes HER2 an attractive therapeutic target in HER2-positive patients8. Indeed, HER2
targeted therapy has improved the prognosis and outcome for breast cancer patients in the past
decade9.
Tumor suppressor genes typically function as negative regulators of cancer cell
proliferation, which is critical for preventing normal cells from malignant transformation.
Inactivation or reduction of tumor suppressor genes that result from loss-of-function mutations
contributes to cancer progression3. The most frequently mutated tumor suppressor gene across all
cancer types, including breast cancer, is tumor protein p53 (encoded by TP53)2,10,11. Upon DNA
damage or other stress, p53, a transcription factor, activates a wide range of cellular pathways to
3

maintain genome integrity and prevent tumor formation. The trans-activated pathways include
apoptosis, cell cycle arrest, autophagy, anti-oxidant defense, etc. The loss of p53 function through
global transcriptional and translational repression leads to tumorigenesis12. Although inactivation
of tumor suppressor genes is more predominately found than over activation of oncogenes in
tumors, it is more difficult to attack cancer cells with loss-of-function mutations than those with
gain-of-function mutations. Restoring the function of tumor suppressor genes remains a difficult
task in cancer therapy.
Cancer is a complex and dynamic ecosystem with mutational, spatial, and temporal
heterogeneity. The heterogeneity can be exemplified by how passenger mutations can be a doubleedged sword in the therapeutic resilience of cancer. Passenger mutations are usually hidden inside
a tumor before treatment, but some of these mutations may convert to driver mutations and
promote cancer regrowth once the selective environment is changed5. On the other hand, passenger
mutations can serve as patient- and tumor-specific neoantigens that boost the ability of endogenous
T cells to destroy cancer cells13. The mixed roles of passenger mutations are just the tip of the
iceberg in regards to the complexity of cancer. To comprehensively address the heterogeneity and
complexity of human cancer, conducting genome-wide analysis in human cancer is imperative.

1.2
Genomics empowers the elucidation of the
molecular architecture and driver candidates in human
cancers
Advances in high-throughput sequencing and bioinformatic technologies have
dramatically improved our understanding of molecular aberrations in human malignancies in
recent years. When the first complete draft of the human reference genome was released in 200414,
it became possible to assess cancer genomes, at single-base resolution. In general, genomic DNA
or RNA isolated from tumor samples are sequenced and compared with those from matched
4

normal tissues. Through comparison, different types of genetic alteration are identified, including
single nucleotide variants (SNVs), insertions or deletions (INDELs), structural rearrangements,
and copy-number alterations. Moreover, regions of genomes that differ frequently enough are
considered as potential causal variants that lead to malignancy. Since the first whole-genome
comparison of an acute myeloid leukemia patient was published in 200815, more and more cancer
genomes have been sequenced and are available for further investigation.
Extensive national or international collaboration projects, such as The Cancer Genome
Atlas (TCGA) or the Clinical Proteomic Tumor Analysis Consortium (CPTAC), have been
established to promote the generation, analysis, and sharing of cancer genome sequencing data.
The US-based TCGA aims to assess the genomic, transcriptomic, and epigenomic aberrations in
100 to 1,000 tumors from each of 33 cancer types. The CPTAC project also seeks to study those
aberrations in cancer cells across 10 different cancer types with an emphasis of large-scale mass
spectrometry-based proteome data. These large consortia have made a giant leap in cancer genome
analysis in several ways. First, the well-coordinated workflows for sequencing and processing
avoid redundant and laborious effort in generating omics data. Second, processed data are widely
accessible to all investigators, facilitating data sharing and interpretation. Third, the multiple data
types that were extracted from the same set of samples allow researchers to perform integrative
analysis easily in a quality-controlled fashion. Finally, by providing a large number of samples for
each cancer type, the consortia improved the statistical power in detecting driver mutations. As a
result, the large-scale projects from TCGA and CPTAC are invaluable resources for systematic
characterization of cancer genomes16.
Analyses of the sequenced cancer genome have generated several statistics on mutation
patterns of human cancer. Each solid tumor has an average of 33 to 66 genes having non5

synonymous somatic mutations, and about 95% of these mutations are SNVs3. There are at least
299 genes identified as significantly mutated genes across 33 cancer types, suggesting that those
genes are associated with tumorigenesis in a particular tumor or multiple tumors1. The number of
cancer-associated genes is still growing as samples and cancer types are added. The compiled
statistics also revealed that different cancers have distinct genomic properties in terms of mutation
frequency of single-point mutations, collection of frequently mutated genes, and mutational
spectrum, to name a few2,17. For example, in regards to mutation frequency, melanomas and lung
tumors contain approximately 200 nonsynonymous mutations per tumor due to the involvement
of potent mutagens, while pediatric tumors and leukemias have around 10 mutations per tumor3.
Those studies highlight the complex nature of human cancers and serve as foundation for
subsequent in-depth investigations of mutational patterns both across and within individual tumor
types.
The use of algorithms to pinpoint cancer-driving variants before experimental validation is
important in the mining of cancer genomes. With the knowledge inferred from evolutionary
conservation, protein domain analysis, and cancer-associated cellular pathways, prioritization of
non-synonymous variants based on their likely damaging effect is well established in variant
interpretation18. The most common strategy for identifying coding driver candidates is first to map
non-synonymous variants to protein-coding regions, and then search recurrently mutated genes in
a cohort of cancer patients. A recurrence pattern suggests that those mutations underwent positive
selection during tumorigenesis19,20. Other strategies to detect signals of cancer gene positive
selection includes conservation of the nucleotide or amino acid sequence relative to other
sequenced species, functional impact prediction on the encoded protein, and combination of
mutations at the pathway/network level, etc. Integrating two or more signals of positive selection
6

based on their complementary biological features has been demonstrated to improve the prediction
accuracy of each individual approach, and holds great potential for finding reliable driver genes21.
With the progress in sequencing technique, collaborative analyses, and bioinformatic
development, a genomic era of cancer studies is developing rapidly, providing an unprecedented
opportunity to comprehensively characterize the human malignancies. However, most of the
studies concentrate on recurrent and somatic mutations in the coding fraction of the cancer genome,
which represents only 2% of the human genome. Although the work remains incomplete,
understanding the cancer features outside of coding regions is an important next step for gaining
deeper insight into the cancer genome landscape. Therefore, we set out to systematically elucidate
several less explored features in cancer genome, including DNA slippage events at microsatellite
sequences, gene fusions arising from genomic rearrangements, and aberrant DNA methylations at
promoter regions (Figure 1).
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1.3

Figures

Characterize the hidden landscape of cancer genome
The Cancer Genome Atlas (TCGA)
• 10,980 TCGA tumors
• 33 cancer types
• WXS, RNA-seq, DNA methylation

Clinical Proteomic Tumor Analysis
Consortium (CPTAC)
• 506 CPTAC tumors
• 5 cancer types
• WXS, RNA-seq, DNA methylation,
Proteomic data
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Chapter 2: Diverse impacts of microsatellite
instability across 33 cancer types
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*indicates co-first authors
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2.1 Abstract
The DNA mismatch repair (MMR) system corrects erroneous insertions, deletions, and
substitutions during DNA replication. MMR deficiency is the canonical cause of microsatellite
instability (MSI) in hereditary and sporadic colorectal and endometrial cancers, but the molecular
and clinical consequences of MMR deficiency in other cancer types have not been extensively
characterized.. Here, we present an analysis of genomic and epigenomic alterations in 39 MMRrelated genes and their downstream effects in over 10,000 human cancers. We find that mutation
and methylation status of MMR genes has cancer type-specific effects on point mutation frequency
and gene expression. Further, using an NGS-based tool to determine microsatellite instability (MSI)
status of diverse cancers, we relate MMR status to MSI. Finally, we relate immune response and
clinical outcome to MMR status, and suggest a possible mechanism by which MMR deficient
cancers demonstrate a brisk response to immunotherapy.

2.2

Introduction

The DNA mismatch repair (MMR) machinery maintains genomic stability by correcting
erroneous insertions, deletions, and base substitutions during DNA replication. A set of
evolutionarily conserved core proteins, including MLH1, MLH2, PMS2, and MSH6, recognize
the distortions of the helical structure caused by mismatches, direct MMR machinery onto the
freshly replicated DNA strand that contains the errors, remove several nucleotides of DNA
containing the mismatch, and correctly resynthesize and ligate the DNA1. When genes in the MMR
machinery malfunction, mutations accumulate, and a phenotypic hallmark of MMR deficiency
occurs, that is microsatellite instability (MSI).
Microsatellite are repetitive sequences of DNA with a unit length ranging from one to six
bases in discrete sites throughout the genome. Since those sites are particularly vulnerable to errors
13

during DNA replication, MSI is introduced when MMR machinery is dysfunctional. MSI is an
abnormal extension and shortage of tandem repeats when compared to normal, which has been
identified and characterized as an important biomarker in several cancer pathological associations.
MSI is observed in about 20% of gastrointestinal, 30% of endometrial, and 15% of colorectal
cancers1.
MSI has traditionally been assessed using the reference Bethesda panel of 5 or 7 repeat
markers. While PCR-based methods using Bethesda criteria are the gold standard for MSI
detection, they are expensive, optimized for colorectal and endometrial cancers only, and limited
to a small subset of microsatellites. Next-generation sequencing has enabled genome-wide MSI
profiling. Because MSI and other hypermutator phenotypes are predictors of response to
immunotherapy, there has been renewed interest in characterizing MSI across cancer types using
NGS tools. For example, a recent effort profiled instability signatures in microsatellites across
coding regions from 6,747 human tumors. The number and patterns of microsatellites can
distinguish MSI-high tumors from microsatellite stable tumors2.
Using MSIsensor3, a software tool that quantifies MSI in paired tumor-normal genome
sequencing data, we characterized the mutational landscape and MSI status across cancer types,
and relate these patterns to somatic and germline mutations in MMR genes. We then identified the
contributions of mutations and epigenetic changes in individual MMR genes to the MSI and
hypermutator phenotypes. Finally, we examined the clinical consequences of MMR-deficient
tumors as it relates to immunogenicity.
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2.3

Results

2.3.1
types

Identify canonical and noncanonical MSI tumors across 33 cancer

We determined the MSI landscape in cancer patients by analyzing the TCGA exome
sequencing data from 9,423 tumors and matched normal pairs across 33 cancer types. MSI status
was first quantified by MSIsensor score and characterized as MSI-High (score > 10), MSI-Low
(3.5 < score <10), and microsatellite stable (score < 3.5). As expected, most of the MSI-High/MSILow tumors are from the five well-characterized canonical MSI-prone tumor types (Figure 1),
namely UCEC (31.1%), STAD (18.8%), COAD (17.8%), READ (6.8%), and ESCA (1.6%).
MSIsensor results in these cancers agreed well with orthogonal MSI-PCR clinical status reported
by TCGA (p=1.9e-198, Fisher's exact test, Figure 2). Notably, we also identified a few MSIHigh/MSI-Low tumors in other non-canonical MSI tumor types, such as KICH (12.1%), PAAD
(6.0%), OV (3.4%), KIRC (1.8%) and BRCA (1.3%). These observations suggest the more general
importance of taking MSI status into consideration, even for noncanonical cancer types, which
currently appear to be overlooked in analysis and clinical prognosis.
In order to assess the difference between exome-based and WGS-based MSIsensor scores,
we also inferred the latter from available WGS data from 932 tumors and matched normal pairs in
parallel (Figure 3). Score correlations varies by cancer type, with UCEC, STAD, DLBC, SARC,
SKCM, LUSC, KIRP, and COAD showing good agreement (R2 ranges from 0.94 to 0.47) and
others showing mediocre to poor agreement (R2 < 0.42).

2.3.2
Canonical and noncanonical MSI tumors are associated with
elevated mutation rate and MMR deficiency in a lineage-dependent
manner
To further distinguish the determinants and consequences between canonical and
noncanonical MSI tumors, we investigated the mutation rates and its relationship with MMR
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deficiency. We systematically profiled point mutations in coding regions to estimate the incidence
of somatic mutation (Figure 4A). As expected, most of the canonical MSI tumors have
significantly higher number of point mutations (median = 965 point mutations) than noncanonical
MSI tumors and non-MSI tumors, confirming canonical MSI tumors are hypermutators. Although
the number of point mutations of noncanonical MSI tumors (median = 677 point mutations) is
significantly lower than canonical MSI tumors, it remains significantly higher than that of nonMSI tumors. Our result suggests that noncanonical MSI tumors are associated with hypermutators,
indicating a lineage-dependent response of MMR deficiency.
Next, we south out to relate the deleterious mutations on MMR genes to MSI tumors
without MLH1 hypermethylation. The majority of canonical MSI tumors have mutated POLE
(n=25) or POLD1 (n=17) (Figure 4B), in line with the finding that POLE and POLD1 are
consistently more prevalent in MSI tumors4. Notably, the majority of noncanonical tumors have
mutated MLH1 (n=11), POLE (n=6), LIG1 (n=5), and MLH3(n=5) (Figure 4C). Our analysis
shows that canonical and noncanonical MSI tumors have distinct mutational patterns of MMR
genes, suggesting that the determinants of the two MSI tumor groups are likely lineage-dependent.
As an independent validation of the canonical and noncanonical MSI tumors, we used the
Clinical Proteomic Tumor Analysis Consortium (CPTAC) exome data of 993 samples across 7
cancer types. MSIsensor estimation of MSI status in tumors versus normal tissue confirmed the
identification of canonical (COAD and UCEC) and noncanonical (BRCA) MSI tumors, where
those MSI tumors are associated with high mutation rate (Figure 5). The result independently
validating the presence of not only canonical but also noncanonical MSI tumors.
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2.3.3
Microsatellite-derived neoantigen from canonical and
noncanonical MSI tumors are immunogenic
MSI tumors show improved response to immune checkpoint therapy, independent of
histology5. In order to estimate the immunotherapy efficacy of canonical and noncanonical MSI
tumors, we identified the microsatellite-derived neoantigens predicted to bind with MHC proteins
by using pVAC-seq6 (Figure 6A). The number of neoantigens varied between canonical and
noncanonical MSI tumors (Figure 6B), where correlated positively with MSIsensor score in
canonical MSI tumors and trended positive in BRCA but not GBM or KIRC. This result suggests
that microsatellite instability leads to excess neoantigen load both in canonical and noncanonical
MSI tumors, but varies based on tissue of origin.

2.4

Discussion

Despite the use of immune checkpoint inhibitors to treat cancers in recent years, it is still
difficult to precisely select patients who will benefit from immunotherapy, even among those
patients with overexpressed PD-L1. MSI might be an important molecular feature for
responsiveness to immune checkpoint inhibition. Our comprehensive analysis of MSI across
multiple cancer types corroborates the known relationship among microsatellite instability, tumor
mutational burden, and expression of immune modulators, but also suggests additional groups of
MSI tumors from noncanonical cancer types. The modest MSI phenotype of noncanonical cancer
types indicates potential therapeutic implications, which has been partially tested in the neoantigen
load analysis section. The excess neoantigen load of MSI tumors predicted by genomics-based
methods could be further validated by orthogonal proteomic evidence7. Our results also show that
there are several subtypes of MSI tumors, i.e. canonical and noncanonical MSItumors, that may
be distinguished by the particular MMR component that is defective, which in turn could influence
MSI and responsiveness to therapy. Together, the increased number of microsatellite-associated
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neoantigens resulting from MMR deficiency may be more permissive to anti-PD-1 therapy in this
genetically defined subset of cancers.

2.5

Methods

2.5.1 Data Preparation for TCGA samples
A publicly available MAF file was compiled by the MC3 Working Group and is annotated
with filter flags to highlight potential artifacts or discrepancies. This dataset represents the most
uniform attempt to systematically provide mutation calls for TCGA tumors. The MC3 effort
provided consensus calls from 7 software packages 8. Flagged artifacts include: non-exonic regions,
whole-genome amplified (WGA) samples, exclusion lists, blood/tumor derived pairs, strand-bias,
contamination estimations, oxo-guanine artifacts, low normal read depth, polymorphisms common
in EXAC, mutations present in a panel of normal samples, non-preferred tumor normal pairs, and
mutations outside the regions of interest for any caller. If a mutation was not assigned any flag and
was called by 2 or more variant calling software packages, it received a ‘PASS’ identifier. We
restricted our analysis to PASS calls with the exception of samples from OV and LAML, which
were some of the earliest sequenced by TCGA. Preparations for these samples utilized whole g
enome amplified (WGA) DNA, an important factor in that the WGA process can induce artifactual
mutations. Of the 412 OV and 141LAML samples present in our data 347 (84%) and 141 (100%),
respectively, had variants derived from WGA DNA. In order to maintain sample sizes and
uniformity in mutation calling, we did not filter mutations containing only ‘wga’ filter tags from
these two cancer types. The final driver-discovery dataset consisted of 9,079 samples having a
total of 791,637 missense mutations, 323,884 silent mutations, 96,196 3’UTR mutations, 57,900
nonsense mutations, 42,251 intronic mutations, 42,251 Frameshift deletions, 34,266 5’UTR,
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21,804 splice site mutations, 19,856 RNA mutations, 11,305 frameshift insertions, 7,622
3’flanking mutations, 6,419 5’flankingmutations, 6,144 in-frame deletions, 1,362 translation start
site mutations, 964 nonstop mutations, and 632 in-frame insertions.
These 33 cancer types included in this study are adrenocortical carcinoma [ACC], bladder
urothelial carcinoma [BLCA], brain lower grade glioma[LGG], breast invasive carcinoma
[BRCA], cervical squamous cell carcinoma and endocervical adenocarcinoma [CESC],
cholangiocarcinoma [CHOL], colon adenocarcinoma [COAD], esophageal carcinoma [ESCA],
glioblastoma multiforme [GBM], head and neck squamous cell carcinoma [HNSC], kidney
chromophobe [KICH], kidney renal clear cell carcinoma [KIRC], kidney renal papillary cell
carcinoma [KIRP], acute myeloid leukemia [LAML], liver hepatocellular carcinoma [LIHC], lung
adenocarcinoma [LUAD], lung squamous cell carcinoma [LUSC], lymphoid neoplasm diffuse
large B cell lymphoma [DLBC], mesothelioma [MESO], ovarian serous cystadenocarcinoma [OV],
pancreatic adenocarcinoma [PAAD], pheochromocytoma and paraganglioma [PCPG], prostate
adeno-carcinoma [PRAD], rectum adenocarcinoma [READ], sarcoma [SARC], skin cutaneous
melanoma [SKCM], stomach adenocarcinoma [STAD], testicular germ cell tumors [TGCT],
thymoma [THYM], thyroid carcinoma [THCA], uterine carcinosarcoma [UCS],uterine corpus
endometrial carcinoma [UCEC], and uveal melanoma [UVM].

2.5.2 Data Preparation for CPTAC samples
We collected the processed and normalized genomic and proteomic data generated for the
analysis from the publications of each cohort. Our data collection includes:
CPTAC2 BR prospective (submitted)
CPTAC2 CO prospective9
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CPTAC2 OV prospective10
CPTAC3 ccRCC discovery11
CPTAC3 LUAD discovery12
CPTAC3 GBM discovery (submitted)
CPTAC3 UCEC discovery13

Some preprocessing steps were applied to harmonize the data across cohorts. Samples excluded in
the original publications were removed. The protein abundance was kept unique per gene symbol.
Peptides that don’t match the site location or the exact protein sequence were removed.
Modification sites per peptide were named using the pattern “<gene symbol>:<protein
id>:<sites>.<duplication>”, where duplicated sites were ordered by the detection percentage
across the cohort. Peptides detected in < 20% of the samples were removed.

The peptide search databases of these cohorts include RefSeq 20160914 (CPTAC2 BR and OV
prospective), RefSeq 20171003 (CPTAC2 CO perspective), and RefSeq 20180629 (all CPTAC3
cohorts). To facilitate the cross-data interpretation, we improved the annotation of the databases
by recovering HGNC Gene IDs from NCBI/Entrez Gene IDs using HGNC BioMart
(https://biomart.genenames.org/) and retrieving the UniParc IDs and checksums for all the protein
sequence in all databases (DOI: 10.1093/bioinformatics/bth191). Note that we keep the gene
symbols identical to the RefSeq records at the time of download.

2.5.3 Creation of MMR Gene Set
We listed all the 39 genes involved in the MMR pathway by manually literature review.
The genes were grouped based on functional complexes as follows.
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MutS complex: MSH2, MSH6, MSH3, MSH4, MSH5.
MutL complex: MLH1, PMS2, MLH3.
Polymerase: POLD1, POLD3, POLE, POLE2, POLE3, POLE4, POLK
Others: MGMT, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, PMS1, PMS2L3, PMS2P,
RFC1, RFC2, RFC3, RFC4, RFC5, RPA1, RPA2, RPA3, RPA4, RPA, LIG1, PCNA, RFC, EXO1.

2.5.4 Estimate MSI Status By Using MSIsensor
MSIsensor3 is a C++ algorithm that distinguishes microsatellite unstable tumors from
microsatellite stable samples based on tumor/normal sequence data. Homopolymer regions of 5 or
more nucleotides in length are aggregated separately in tumor/normal pairs and compared using a
chi-square statistic. MSI-high was calculated as an MSI score greater than 3.5. Parameters for
running MSIsensor ‘‘msi’’ command are as follows: –l (minimal homopolymer size) = 1 and –q
(minimal microsatellitesize) = 1. These settings are not a minimal number of repeats, but rather
the minimal number of nucleotides to consider within the repeat. 357 scores were generated from
BAM files other than those used for variant calling by the MC3 Working group.

2.5.5 HLA Typing and Neoantigen Prediction From Microsatellite Sites
HLA class I typing of CPTAC samples was determined by using OptiType14 tool. OptiType
was run under its default parameters for RNA sequencing FASTA files. For each predicted
microsatellite passed chi-square test, we obtained translated protein sequences for novel transcripts
from VEP v97 (Ensembl Variant Effect Predictor) using default setting15. We constructed different
epitope lengths (8-11-mer) from the translated protein sequence. We predicted the binding affinity
between epitopes and the major histocompatability complex (MHC) using pVAC-seq docker
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version6. Epitopes with binding affinity smaller than 500nM which are also not present in the wildtype transcript are reported as neoantigens.
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Chapter 2
Figure 2.1 Relationship among MMR deficiency, mutation frequency, and MSI status across 21 cancer types.

Tumor mutational burden (upper) and MSI scores (middle) segregated by cancer types. The
fraction of MSI prone tumors explained by MMR deficiency is displayed on the lower panel. Each
dot represents one cancer sample. Dots are color-coded based on the presence of one or more
somatic or germline mutations in an MMR gene, or on MLH1 promoter hypermethylation. MSI
score threshold is displayed with a dashed horizontal line.
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Figure 2.2 Quantitative MSIsensor scores correlated with qualitative results from gel-assay

Histogram shows distribution of log2-transformed MSI score. Samples are colored by the
clinical classification experimentally validated by TCGA.
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Figure 2.3 Exome-based and WGS-based MSIsensor scores are correlated.

Correlation between exome-based and WGS-based MSIsensor scores segregated by cancer types.
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Figure 2.4 Canonical and noncanonical MSI tumors are significantly associated with high mutational burden.

(A) Number of point mutations stratified by MSI status. Boxplots indicate median number of
point mutations with 25th and 75th percentile hinges and whiskers that extend to 1.5*IQR.
(B) Number of canonical MSI tumors with indicated mutations (missense: left panel, truncation:
right panel) segregated by MMR genes.
(C) Number of noncanonical MSI tumors with indicated mutations (missense: left panel,
truncation: right panel) segregated by MMR genes.
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Figure 2.5 Canonical and noncanonical MSI tumors are validated in independent dataset.

Number of point mutations stratified by MSI status in canonical and noncanonical cancer types.
Boxplots indicate median number of point mutations with 25th and 75th percentile hinges and
whiskers that extend to 1.5*IQR.
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Figure 2.6 Microsatellite-derived neoantigens are potentially immunogenic.

(A) Flowchart of microsatellite-derived neoantigens identification pipeline.
(B) Correlation between number of neoantigens and MSIsensor score segregated by cancer
types.
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Chapter 3: Driver Fusions and Their
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3.1

Abstract

Gene fusions represent an important class of somatic alterations in cancer. We
systematically investigated fusions in 9,624 tumors across 33 cancer types using multiple fusion
calling tools. We identified a total of 25,664 fusions, with a 63% validation rate. Integration of
gene expression, copy number, and fusion annotation data revealed that fusions involving
oncogenes tend to exhibit increased expression, whereas fusions involving tumor suppressors have
the opposite effect. For fusions involving kinases, we found 1,275 with an intact kinase domain,
the proportion of which varied significantly across cancer types. Our study suggests that fusions
drive the development of 16.5% of cancer cases and function as the sole driver in more than 1%
of them. Finally, we identified druggable fusions involving genes such as TMPRSS2, RET, FGFR3,
ALK, and ESR1 in 6.0% of cases, and we predicted immunogenic peptides, suggesting that fusions
may provide leads for targeted drug and immunotherapy.

3.2

Introduction

The ability to determine the full genomic portrait of a patient is a vital prerequisite for
making personalized medicine a reality. To date, many studies have focused on determining the
landscape of single nucleotide polymorphisms, insertions, deletions, and copy number alterations
in cancer genomes1–6. While such genomic alterations make up a large fraction of the typical tumor
mutation burden, gene fusions also play a critical role in oncogenesis. Gene fusions or
translocations have the potential to create chimeric proteins with altered function. These events
may also rearrange gene promoters to amplify oncogenic function through protein overexpression
or to decrease the expression of tumor suppressor genes.
Gene fusions function as diagnostic markers for specific cancer types. For example, a
frequent translocation between chromosomes 11 and 22 creates a fusion between EWSR1 and FLI1
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in Ewing’s sarcoma. Also, the Philadelphia chromosome 9-22 translocation is characteristic of
chronic myeloid leukemia, resulting in the fusion protein BCR--ABL1. This fusion leads to
constitutive protein tyrosine kinase activity and downstream signaling of the PI3K and MAPK
pathways, which enables cells to evade apoptosis and achieve increased cell proliferation7–10.
Fibrolamellar carcinoma (FLC) in the liver is characterized by a DNAJB1--PRKACA fusion. A
recent study of TCGA tumors revealed this fusion transcript is specific to FLC, differentiating it
from other liver cancer samples6. In contrast, FGFR3--TACC3 is an inframe activating kinase
fusion found in multiple cancer types, including glioblastoma multiforme (GBM)11,12 and
urothelial bladder carcinomas (BLCA)13. Other recurrent fusions have also been reported in
multiple cancer types14–16, and functional characterization of a few selected fusion genes in cellular
model systems has confirmed their oncogenic nature17.
Recently, large-scale genomic studies have utilized the TCGA RNA-Seq data corpus to
systematically identify and compile fusion candidates across many cancer types. For example, as
part of its goal to develop a comprehensive, genome-wide database of fusion genes, ChimerDB18
has analyzed RNA-Seq data of several thousand TCGA cases. Giacomini et al. performed
breakpoint analysis on exon microarrays across 974 cancer samples and identified 198 candidate
fusions in annotated cancer genes19. A searchable portal of TCGA data includes 20,731 fusions
called from 9,966 cancer and 648 normal samples20. Some studies focus on important classes of
genes, such as kinase fusions21, which may have particular structural properties that are selected
for during oncogenesis and cancer progression. However, most efforts have utilized only a single
fusion calling algorithm. Since disagreements among different callers are common, there is a need
to develop a comprehensive approach that combines the strengths of various callers to achieve
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higher fusion calling accuracy. Further, large-scale analyses are likely to expand the targetable
landscape of fusions in cancer, revealing potential treatment options for patients.
Here, we leverage multiple newly-developed bioinformatic tools to methodically identify
fusion transcripts across the TCGA RNA-Seq data corpus using the ISB Cancer Genomics Cloud.
These tools include STAR-Fusion, Breakfast, and EricScript (STAR Method),. Fusion calling
across 9,624 TCGA tumor samples from 33 cancer types identified a total of 25,664 fusion
transcripts, with 63.3% validation rate for the samples having available whole genome sequencing
data. Further, we investigated the relationship between fusion status and gene expression, the
spectrum of kinase fusions, mutations and fusions found in driver genes, and fusions as potential
drug and immunotherapy targets.

3.3

Results

3.3.1
Fusion detection pipeline and WGS-based validation of a subset of
fusion predictions
We analyzed RNA-Seq data from 9,624 tumor samples and 713 normal samples from The
Cancer Genome Atlas (TCGA) using STAR-Fusion (STAR Method), EricScript22, and Breakfast
(STAR Methods, Table S1). A total of 25,664 fusions were identified after extensive filtering using
several panel-of-normals databases, including fusions reported in TCGA normal samples, GTEx
tissues23 and non-cancer cells24 (STAR Methods, Fig. 1A, and Table S1). Our pipeline detected
405 out of 424 events curated from individual TCGA marker papers (Table S1) (95.5% sensitivity).
We further cross-confirmed our transcriptome sequencing-based fusion detection pipeline
by incorporating whole genome sequencing (WGS) data, where available. WGS paired-end reads
aligned to the partner genes of each fusion were used to validate fusions detected using RNA-Seq.
Using all available whole-genome sequencing, including both low-pass and high-pass data, from
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1,725 of the 9,624 cancer samples across 25 cancer types, we were able to evaluate 18.2% (4,675
fusions) of our entire fusion call set. Of that subset, WGS validated 63.3% of RNA-Seq based
fusions by requiring at least three supporting discordant read pairs from the WGS data (Figure S1).

3.3.2

Fusion landscape across 33 cancer types

Categorizing the 25,664 fusions based on their breakpoints, we found that the majority of
breakpoints are in coding regions (CDS) of both partner genes (Fig. 1B). Surprisingly, there are
many more fusions in 5’ UTRs compared to 3’ UTRs for both partner genes, given that 3’ UTRs
are generally longer (Mann-Whitney U Test, p<2.2e-16). This could be explained by having more
open chromatin in the 5’ UTR region25, the larger number of exons in 5’ UTRs than 3’UTRs
(Mann-Whitney U Test, p<2.2e-16)26, but could also indicate some regulatory mechanisms, e.g.
alternative usage of the promoter region of a partner gene.
For different cancer types, the total number of fusions per sample varies from 0 to 60, with
a median value of one (Figure S1). Cancer types having the fewest number of fusions per sample
are kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary
cell carcinoma (KIRP), low grade glioma (LGG), pheochromocytoma and paraganglioma (PCPG),
testicular germ cell tumors (TGCT), thyroid carcinoma (THCA), thymoma (THYM), and uveal
melanoma (UVM), each with a median of zero. Other cancer types show a range of medians
between 0.5 and 5 fusions per sample, although most samples demonstrate zero or only one
inframe, disruptive fusion relevant to oncogenesis.
Frequencies of recurrent fusions found in each cancer are illustrated in Figure 1C (Table
S1). The most recurrent example within any cancer type was TMPRSS2--ERG in prostate
adenocarcinoma (PRAD, 38.2%). We found FGFR3--TACC3 to be the most recurrent fusion in
BLCA (2.0%), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC, 1.7%),
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and lung squamous cell carcinoma (LUSC, 1.2%). Other top recurrent fusions include EML4-ALK in lung adenocarcinoma (LUAD, 1.0%), CCDC6--RET in THCA (4.2%), and FGFR2-BICC1 in cholangiocarcinoma (CHOL, 5.6%).

3.3.3

Fusion gene expression in oncogenes and tumor suppressors

Fusion events may be associated with altered expression of one or both of the fusion gene
partners, a well-known example being multiple myeloma tumors in which translocation t(4;14)
fuses the highly-expressed IGH locus with the tyrosine protein kinase FGFR327. We integrated
gene expression, copy number, and fusion annotations to systematically test for associations
between gene expression and fusion status.
For each fusion having an oncogene, kinase, or tumor suppressor (Table S2), we
determined whether that sample was an expression outlier for that gene and subsequently examined
resulting percentages of both under- and overexpressed genes in each cancer type (Table S3).
Figure 2A shows that between 6% (mesothelioma, MESO) and 28% (KIRP) of kinase fusions
displayed outlier overexpression of the kinase partner. Oncogenes tended to show higher
likelihoods of overexpression, while tumor suppressors displayed lower likelihoods. Between 3%
(breast invasive carcinoma, BRCA) and 38% (PCPG) of tumor suppressor gene fusions showed
outlier under expression, generally higher than both oncogenes and kinases.
Figure 2B illustrates the median percentile expression level of the most highly recurrent
oncogenes and tumor suppressors involved in fusions (Table S3). Samples with fusions involving
oncogenes, such as EGFR, ERBB2, and RET, showed increased expression of those genes relative
to samples without fusions across cancer types. Most tumor suppressor genes (TSGs) showed
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inconsistent patterns of expression across cancer types. However, the global trend for TSGs is
decreased expression compared to non-fusion samples.
We also examined the relationship between TSG mutations and fusions to determine
whether frequently-fused TSGs were also disrupted by other mutation types. A variety of patterns
were noted. For example, TP53 is affected by mutations rather than fusions in most cancer types.
However, in sarcoma (SARC), both fusions and mutations affecting TP53 were detected. In acute
myeloid leukemia (LAML), several CBFB fusions but no mutations were observed, yet other
cancer types also exhibited CBFB mutations (Table S3, Figure S2). Our results suggest that
alternative mechanisms are utilized by tumor cells in a cancer type-specific manner.
We also observed associations between fusion status and expression level in well-known
fusions (Table S3), such as RET--NTRK1 in thyroid cancer, EML4--ALK in lung cancer21, and
DNAJB1--PRKACA in the fibrolamellar carcinoma subtype of liver cancer28. RET fusions in
thyroid carcinoma (THCA) and lung adenocarcinoma (LUAD) are inframe protein kinase fusions
with overexpression of the 3’ RET oncogene (Fig. 2C). Recurrent CBFB--MYH11 fusions in
LAML are significantly associated with decreased expression of the tumor suppressor CBFB,
which functions as a transcriptional regulator29 (Fig. 2D).
In breast cancer, copy number amplification is a well-known mechanism of ERBB2 overexpression and treatment of these HER2+ patients with trastuzumab is an established and effective
targeted therapy30. Interestingly, three out of four samples with ERBB2 fusions and two samples
without a called fusion showed HPV integration within 1Mb of ERBB231. ERBB2 fusion gene
partners PPP1R1B and IKZF3 are genomic neighbors of ERBB2, suggesting that these fusions
could be a by-product of local instability, pduced by the viral integration and subsequent breakage
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fusion events. By careful analysis of the association between fusions and expression, we have
identified strategies for improving both sensitivity and specificity of fusion calls.

3.3.4

Structure and spectrum of kinase fusions

Some oncogenic kinase fusions are susceptible to kinase inhibitors21, suggesting that
additional therapeutic candidates might be discovered by examining fusion transcripts involving
protein kinase genes. In total, we detected 2,892 such events, comprising 1,172 with kinase at the
3’ end (3’-kinase), 1,603 with kinase at the 5’ end (5’-kinase), and 117 with both partners being
kinases (both-kinase) (Fig. 3A and Table S4). Analysis of the catalytic kinase domains using the
UniProt/PFAM domain database (STAR Methods) showed that 1,275 (44.1%) kinase fusions
retained an intact kinase domain (Fig. 3A). We further predicted open reading frames for these
fusions and separated them into three categories with respect to the frame of the 3’ gene: inframe,
frameshift, and no frame information (e.g. breakpoint at UTR, intron, or non-coding RNA). In
general, there were more inframe fusions than frameshift fusions, especially for 3’-kinase fusions,
because preserving the reading frame is required to keep the kinase domain intact. For subsequent
kinase analyses, we focused only on those 1,275 fusions having intact domains, further classifying
the both-kinase group into 3’-kinase or 5’-kinase based on the position of the intact domain.
Comparison of kinase fusions across different cancer types indicated that kinase fusions
are significantly enriched in thyroid carcinoma (THCA, 35.6%, Fisher’s Exact Test, p < 2.2e−16)
(Fig. 3B). Moreover, the majority were 3’-kinase fusions (94.0%), a significantly higher
percentage than what we observed in other cancer types (Fisher’s Exact Test, p < 2.2e−16). We
further divided these fusions into eight categories based on different kinase groups, including AGC,
CAMK, CK1, CMGC, STE, TK, TKL. In general, we found that the percentages of different
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categories vary across cancer types (Fig. 3B). For example, there are more TK fusions in THCA
and GBM, more CK1 fusions in uterine corpus endometrial carcinoma (UCEC), colon
adenocarcinoma (COAD), and esophageal carcinoma (ESCA), and more AGC fusions in liver
hepatocellular carcinoma (LIHC). Across different cancer types, we found an enrichment of TK
and TKL kinase fusions for 3’-kinases, but no strong preference for 5’-kinases (Figure S3).
Recurrent kinase fusions are of great interest as potential drug targets. Overall, we detected
744 5’-kinase and 531 3’-kinase fusions. Of these, 147 and 99 were recurrent, respectively, mostly
across cancer types rather than within cancer types (Figure S3). As expected, fusions in the FGFR
kinase family (FGFR2 and FGFR3) are the most frequent 5’-kinase fusions, given their high
recurrence in individual cancer types (Fig. 3C). WNK kinase family fusions (WNK1 and WNK2)
were also detected in multiple cancer types. The WNK family is phylogenetically distinct from the
major kinase families, and there is emerging evidence of its role in cancer development32. Here,
we found a total of 23 WNK family fusions, most of which resulted in higher expression of WNK
mRNA (Figure S4). The increased expression was not generally accompanied by copy number
amplification; for example, neither WNK1 nor WNK2 were amplified in ESCA or LIHC.
Incidentally, ERC1--WNK1 was also detected recently in an independent Chinese esophageal
cancer cohort 70. For 3’-kinase fusions, all the top 10 kinase genes are tyrosine kinases, most of
which are enriched in THCA, including RET, BRAF, NTRK1, NTRK3, ALK, and REF1 (Fig 3C).
FGR fusions were found in 7 samples the same partner gene WASF2, 5 of which showed higher
expression of FGR gene. In these five samples, the breakpoints for the two genes are the same
(5’UTR of both genes) resulting in usage of the stronger WASF2 promoter for the FGR gene.
Interestingly, recurrent MERTK fusions are singletons in each individual cancer type with
TMEM87B and PRKACA fusions are only observed in liver cancer with DNAJB1 (Figure S3).
40

To further understand the regulation of kinase fusions, we compared the gene expression
patterns between the kinase gene and partner gene. There are in total 1,035 kinase fusions with
both gene expression and copy number data available. To control for the effect of copy number
amplification on gene expression, we focused on the fusions with copy numbers between 1 and 3,
including 439 5’-kinase and 339 3’-kinase fusions (Fig. 4A-B). For 5’-kinase fusions, the kinase
gene expression quantiles are uniformly distributed, indicating that the kinase gene expressions in
the samples with fusion are not significantly different from the samples without fusion (Fig. 4A).
However, 3’-kinase genes tend to show higher expression in samples with a fusion compared to
the ones without. To explain this, we classified the fusion events into three categories based on the
relative expression pattern between the kinase gene and its partner in samples from the same cancer
type. Most (66.7%, 293/439) 5’-kinase fusions showed lower expression in the partner gene
compared to the kinase. In contrast, 70.5% (239/339) of 3’-kinase afusions showed higher partner
expression (Fig. 4A-B). Moreover, those 3’-kinase fusions involving a more highly expressed 5’
partner also show higher kinase expression (Fig. 4C). For example, we found a TRABD--DDR2
fusion in one head and neck squamous cell carcinoma (HNSC) sample, which fused the stronger
TRABD promoter with DDR2, resulting in its overexpression (Fig. 4D). This patient could
potentially be treated using dasatinib, which targets overexpressed DDR2 in HNSC33. DDR2
fusions were also detected in another 9 samples from 5 different cancer types, which could be
treated similarly given sufficient DDR2 overexpression (Table S1).

3.3.5

Mutual exclusivity between fusions and mutations

While mutations in oncogenes or tumor suppressors may lead to tumorigenesis, fusions
involving those genes are also an important class of cancer driver events. We systematically
profiled mutations and fusions in 299 cancer driver genes34 (Table S2) to assess the contributions
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of fusion genes in carcinogenesis in the 8,963 TCGA patients that overlap between the mutation
call set (Public MC3 MAF35, Key Resources Table) and our fusion call set. We characterized
patients as having a driver mutation, a mutation in a driver gene, and/or a driver fusion (fusion
involving a driver gene).
Although the majority of cancer cases have a known driver mutation (48.6%, mean 6.8
mutations) or mutations in a driver gene (28.1%, mean 4.2 mutations), we found 8.3% have both
a driver mutation and driver fusion event (mean 5.5 mutations and 1.2 fusions), 6.4% have both a
mutation and fusion in a driver gene (mean 4.2 mutations and 1.3 fusions), and 1.8% have a driver
fusion only (mean 1.1 fusions) (Fig. 5A). This distribution is consistent with the notion that only
a few driver events are required for tumor development2.
We further examined the total number of mutations for samples and observed a low
mutational burden in the group with driver fusion only, which is comparable with the group with
no driver alterations (Fig. 5B). The significant decrease in the numbers of mutations (MannWhitney U Test, p<2.2e-16) reflects the functionality of fusions across multiple cancer types.
Moreover, within cancer types, we observed a range of 0.2% (HNSC) to 14.0% (LAML) of tumors
with fusions but no driver gene mutations. Among those LAML tumors that have fusions and no
driver gene mutations, we identified several well-recognized fusions relevant to leukemia, such as
CBFB--MYH11 (number of samples=3), BCR--ABL1 (n=2), and PML--RAR (n=2). We also
identified the leukemia-initiating fusion NUP98--NSD1 in two LAML tumors36.
We then examined the relationship of fusions and mutations in the same driver gene (Fig.
5C). The result shows that when fusion events are present in a gene, mutations in the same gene
are rarely found, supporting a pattern of mutual exclusivity of the two types of genomic alteration.
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This trend was observed across many patients and many cancer types. Our results suggest that a
considerable number of tumors are driven primarily or solely by fusion events.

3.3.6

Contributions of fusions to cancer treatment

We investigated potentially druggable fusion events in our call set using our curated
Database of Evidence for Precision Oncology (DEPO; Sun, et al. submitted) (Table S5). We
defined a fusion as druggable if there is literature supporting the use of a drug against that fusion,
regardless of cancer type (allowing for “off-label” drug treatment). We found potentially druggable
fusions across 29 cancer types, with major recurrent druggable targets in PRAD (TMPRSS2, 205
samples), THCA (RET, 33 samples), and LAML (PML--RARA, 16 samples) (Fig. 6A). FGFR3
was a potential target (both on-label and off-label) in 15 cancer types. Overall, we found 6.0% of
samples (574/9,624 samples) to be potentially druggable by one or more fusion targeted treatments.
Further study of fusions in human cancer will facilitate the development of precision cancer
treatments.
We analyzed patterns of fusion druggability in LUAD, stratifying by smoking status. In
this data set, 15% of LUAD samples (75 out of 500 samples with known smoking status) were
never smokers, while a significantly higher percentage of never smokers (15 out of 75 samples)
vs. smokers (9 out of 425 samples) were found to have a druggable fusion (Chi-square test, p<1e6) (Fig. 6B). Several FDA approved drugs exist to target ALK fusions in lung and other cancer
types. We observed ALK fusions in 20 samples from 8 cancer types (5 samples in LUAD). In most
cases, fusion status corresponded to copy number neutral overexpression of ALK (Fig. 6D). In 17
out of 20 cases, ALK was the 3’ partner of the fusion pair, with EML4 being the most frequent 5’
partner (7 out of 17).
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ESR1 encodes an estrogen receptor with important and druggable relevance to breast
cancer37. We detected ESR1 fusions in 16 samples from 5 different cancer types (9 samples from
BRCA). Of the 9 BRCA samples, 8 are known be from the Luminal A or B subtypes. We observed
strict mutual exclusivity between ESR1 mutations and fusions (Fig. 5C). Of the 16 fusions, 11 have
ESR1 at the 5’ end, and 5 at the 3’ end. When ESR1 is the 5’ gene in the fusion, the transactivation
(AF1) domain is always included (Fig. 6D). When ESR1 is the 3’ gene, the transactivation (AF2)
domain is always included. Those samples with ESR1 fusion tend of have higher ESR1 expression,
especially in the 9 BRCA samples (Figure S5). Similarly, ESR1 expression is higher when ESR1
is mutated in BRCA, CESC, and UCEC, which are all hormone receptor related cancer types36,38,39.
Further functional study to determine the mechanism of ESR1 fusions could suggest drug
development directions.
Immunotherapy based on tumor-specific neoantigens shows promise in treating cancer
patients40. Gene fusions found in tumor cells can generate peptides, which may serve as neoantigen
candidates. However, patients with known driver fusions may be poor candidates for
immunotherapy due to their reduced mutational burden, especially without clear evidence of
immune cell infiltration and overall immunogenicity. As an exploratory and speculative analysis,
we investigated neoantigens produced by gene fusions41. On average, there were 1.5 predicted
neoantigens per fusion across different cancer types (Figure S6 and Table S5). The mean number
of predicted neoantigens per fusion ranged from 0.33 in KICH to 2.88 in THYM. We also
compared the number of neoantigens for inframe and frameshift fusions (Figure S6). Results show
that frameshift fusions can generate more immunogenic epitopes than inframe fusions (mean value:
2.2 vs 1.0), though nonsense mediated decay might reduce some of this potential difference.
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We further investigated seven fusions for which there were at least four samples having
one or more neoantigen candidates (Figure S6). In particular, TMPRSS2--ERG, CCDC6--RET, and
FGFR3--TACC3 have the highest number of samples with predicted neoantigen candidates. Our
results show that the fusion product is only immunogenic in a small subset of patients, especially
for TMPRSS2--ERG fusions. Again, without clear evidence of immune cell infiltration and overall
immunogenicity, any fusion neoantigen analysis remains exploratory and speculative.

3.4

Discussion

In this study, we applied multiple RNA-Seq fusion callers, namely STAR-Fusion,
EricScript, and Breakfast, followed by a stringent filtering strategy, to identify potential driver
fusion events across 33 cancer types. We were able to successfully identify 95.5% of fusions
reported in TCGA marker papers. While existing studies have published fusion calls across the
TCGA cancer cohort20,21, we have improved on prior analyses by integrating results across
multiple fusion callers and by applying stringent filtering to derive a confident dataset of fusion
events from 9,624 tumor samples. Importantly, we investigated the biology and evaluated the
significance of fusions in the cancer context. Of the 25,664 fusions we detected, 18.2% could be
tested for validation using available whole-genome sequencing data, leading to a 63.3% validation
rate.
By integrating gene expression, copy number, and fusion annotation data, we evaluated the
biological and therapeutic implications of fusion events. Kinase and oncogene related fusions
tended to be overexpression outliers, while fusions involving tumor suppressor genes showed the
opposite effect overall. When comparing fusion events to the remainder of the cancer cohort,
fusions involving oncogenes such as EGFR, ERBB2, and RET had increased expression.
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Overexpressed fusions, especially inframe kinase fusions, are commonly targeted for therapy due
to their susceptibility to kinase inhibitors.
For all 2,892 kinase fusions, we translated the resulting peptide sequence, finding that
1,275 had functional catalytic kinase domains. Comparison of kinase fusions across different
cancer types showed that THCA has significantly more kinase fusions, most of which were 3’
kinase fusions. In addition to well-known recurrent fusions like FGFR3--TACC3, we also detected
245 kinases with recurrent fusions to different partner genes, which may ultimately prove to be
successful drug targets.
We showed that a meaningful percentage of patients (16.8%) harbor fusions involving
cancer driver genes but have no driver gene mutations. Notably, 6.0% of cancer patients could
potentially benefit from existing drugs targeting fusion products. Moreover, our analysis also
highlights an important consideration for immunotherapy treatment in patients with fusions. The
significant decrease in mutational burden observed in patients with fusions in driver genes points
toward a reduced efficacy of immunotherapy in these patients, despite fusion peptides themselves
potentially being good immunogenic targets. Many fusions are already known to be drug targets.
Our study demonstrates the necessity of performing fusion analysis across multiple cancer
types. Our approach integrated the results of multiple fusion calling algorithms, lending confidence
to fusions with lower levels of RNA-seq read support that might otherwise have been discarded.
We sought to prioritize fusions relevant to cancer by highlighting their association with gene
expression, potential for targeted therapy, and role in cancer hallmark pathways. Fusion allele
frequency is an elusive measure from RNA-Seq data and tracking the clonal evolution of fusions
within a tumor remains an exciting opportunity for study. Fusions play an increasingly appreciated
role in tumorigenesis and progression and represent an important source of improved treatment
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options. Ultimately, our multi-tool, integrative bioinformatic detection approach helps to define
the universe of fusions in cancer. Further, it reminds us that developing robust and widely
applicable clinical diagnostic approaches that can document fusions across cancer types is vital.
Such approaches are critical to identifying those patients who can benefit from both established
treatments and clinical trials.

3.5

STAR Methods

3.5.1 Dataset description
Aligned RNA-Seq bam files were analyzed using the ISB Cancer Genomics Cloud
(https://isb-cgc.appspot.com/). These 33 cancer types included in this study are adrenocortical
carcinoma [ACC], bladder urothelial carcinoma [BLCA], brain lower grade glioma [LGG], breast
invasive carcinoma [BRCA], cervical squamous cell carcinoma and endocervical adenocarcinoma
[CESC], cholangiocarcinoma [CHOL], colon adenocarcinoma [COAD], esophageal carcinoma
[ESCA], glioblastoma multiforme [GBM], head and neck squamous cell carcinoma [HNSC],
kidney chromophobe [KICH], kidney renal clear cell carcinoma [KIRC], kidney renal papillary
cell carcinoma [KIRP], acute myeloid leukemia [LAML], liver hepatocellular carcinoma [LIHC],
lung adenocarcinoma [LUAD], lung squamous cell carcinoma [LUSC], lymphoid neoplasm
diffuse

large

B-cell

lymphoma

[DLBC],

mesothelioma

[MESO],

ovarian

serous

cystadenocarcinoma [OV], pancreatic adenocarcinoma [PAAD], pheochromocytoma and
paraganglioma [PCPG], prostate adenocarcinoma [PRAD], rectum adenocarcinoma [READ],
sarcoma [SARC], skin cutaneous melanoma [SKCM], stomach adenocarcinoma [STAD],
testicular germ cell tumors [TGCT], thymoma [THYM], thyroid carcinoma [THCA], uterine
carcinosarcoma [UCS], uterine corpus endometrial carcinoma [UCEC], and uveal melanoma
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[UVM]. The sample set consists of 10,331 total TCGA samples, 9,624 tumor samples, and 713
normal samples.
Level-3 gene expression (RSEM) and segment-based copy number data were downloaded
from Broad GDAC firehose (https://gdac.broadinstitute.org) (version: 2016_01_28). Gene-based
copy number data were obtained by intersecting with RefSeq gene annotation bed file (version:
2013-07-27). Mutation calls were provided by the Multi-Center Mutation Calling in Multiple
Cancers (MC3) working group within TCGA35 (Key Resources Table).

3.5.2 Fusion detection and filtering
TCGA RNA-Seq data were downloaded from Cancer Genomics Hub (CGHub,
https://cghub.ucsc.edu) and analyzed using the ISB Cancer Genomics Cloud (https://isbcgc.appspot.com/). For each sample, the fastq file was mapped to the human genome (build 38)
followed by fusion calling using STAR-Fusion (parameters: --annotation --coding-effect),
EricScript (default parameters) ( https://sites.google.com/site/bioericscript/) and BREAKFAST
(two

different

minimum

distance

cut-offs

were

used:

5

kb

and

100

kb)

(https://github.com/annalam/breakfast). STAR-Fusion showed higher sensitivity in detecting the
fusions reported in previous TCGA studies. Therefore, we focused on the STAR-Fusion output
and integrated EricScript and BREAKFAST output in one of the following filtering steps: 1) an
exclusion list of genes was curated, including uncharacterized genes, immunoglobulin genes,
mitochondrial genes, etc. Fusions involving these genes were filtered; 2) Fusions from the same
gene

or

paralogue

genes

(downloaded

from

https://github.com/STAR-Fusion/STAR-

Fusion_benchmarking_data/tree/master/resources) were filtered; 3) Fusions reported in normal
samples were filtered, including the ones from TCGA normal samples, GTEx tissues, and non48

cancer cell study24) For the fusions reported by only STAR-Fusion, a minimum value of FFPM >
0.1 (fusion fragments per million total reads) was required, as suggested by the authors; for the
fusions reported by two or more callers, no minimum FFPM was required. 5) Finally, fusions with
the same breakpoints in ³10 samples across different cancer types were removed unless they were
reported in previous TCGA studies.

3.5.3 Validation of fusion transcripts
For fusion events where low-pass whole genome sequencing data or whole genome
sequencing (WGS) data were available from the ISB Cancer Genomics Cloud (https://isbcgc.appspot.com/), we obtained high quality (-q 20) reads mapping to each partner gene and the
100kb region up and downstream using SAMtools. At least 3 discordant reads from WGS were
required to determine if the fusion prediction was validated..

3.5.4 Gene expression analysis
We collected gene expression, copy number, and fusion annotations to test for associations
between gene expression and fusion status. We used Tukey’s definition of outliers to determine if
the expression level at a given gene was an outlier or not. An overexpression outlier means the
sample’s expression level at a given gene was greater than (75th percentile) + 1.5*IQR, where
IQR is the interquartile range. An underexpression outlier means the sample’s expression level at
that gene was less than (25th percentile) - 1.5*IQR. To test for a significant association between
expression and fusion status, we calculated p-values using both a t-test and Fisher’s Exact Test. If
either of those results passed stringent FDR multiple test correction, three or more fusions were
reported, and if the median expression of the fusions was in the top or bottom decile of the data,
we reported those genes for manual review.
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3.5.5 Protein kinase fusion analysis
We curated a list of kinase genes from previous publications and public databases (Table
S5).

Then

we

compared

this

list

with

UniProt/PFAM

domain

database

(http://www.uniprot.org/database/DB-0073) to retain the ones with an annotated kinase domain.
For

the

fusions

involving

kinase

genes,

we

used

AGFusion

(https://github.com/murphycj/AGFusion) to check whether the annotated kinase domain was still
present in the fusion transcript to separate them into fusions with an intact kinase domain versus
those with a disrupted kinase domain. We compared the breakpoint positions in each fusion with
the annotation file to check whether the breakpoint was in the 5’UTR, CDS, or 3’UTR region.
Kinase genes are classified into eight groups: AGC, CAMK, CK1, CMGC, STE, TK, TKL, and
others based on the PhosphoSite Database42. The percentage of kinase genes in each group across
different cancer types was defined as the number of kinase genes with fusions in each group
divided by their sum, denoted as
group was first normalized by

. For each cancer type, the number of kinase genes in each
, denoted as

. Then each number was divided by their sum

to calculate a normalized percentage of kinase genes in each group.

3.5.6 Neoantigen prediction
For each predicted fusion, we obtained translated protein sequences for novel transcripts
from STAR-Fusion. The wild-type protein sequences are obtained from Ensembl Database. We
constructed different epitope lengths (8-11mer) from the translated protein sequence. Each
sample’s HLA type comes from the TCGA Pan-Cancer Immune Group (Synapse ID: syn5974636).
We predicted the binding affinity between epitopes and the major histocompatability complex
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(MHC) using NetMHC441. Epitopes with binding affinity £ 500nM which are also not present in
the wild-type transcript are reported as neoantigens. We required at least 5 splitting reads for
supporting junctions to filter fusions with low expression.

3.5.7 Mutual exclusivity analysis
For TCGA tumor samples where both MC335 (Key Resources Table) mutation calls and
gene fusion calls were available, we obtained the genetic alteration events, including fusion,
inframe deletion, inframe insertion, missense mutation, nonsense mutation, nonstop mutation,
splice site mutation, and translation start site mutation in 299 driver genes. We separated all the
genomic alterations and events into “driver mutation”, “mutation”, and “fusion” categories, and
compiled a genomic alteration profile for each sample. To test if the total number of mutations are
significantly different among groups, we took samples without mutations in the following genes:
POLE, MLH1, MLH3, MGMT, MSH6, MSH3, MSH2, PMS1, and PMS2, to exclude the
confounding factor stemming from microsatellite instability. We then calculated p-values by using
Mann-Whitney U Test.

3.5.8 DEPO
DEPO is a curated list of druggable variants filtered such that each variant corresponds to
one of several categories: single nucleotide polymorphisms or SNPs (missense, frameshift, and
nonsense mutations), inframe insertions and deletions (indels), copy number variations (CNVs) or
expression changes. Each variant/drug entry in DEPO was paired with several annotations of
potential interest to oncologists. DEPO is available as a web portal (http://dinglab.wustl.edu/depo).
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3.6 Figures

Chapter 3
Figure 3.1 Fusion detection and landscape in cancer.

(A) Fusion calling and filtering pipeline.
(B) Cartoon overview of fusion gene partner breakpoints. Purple indicates the 5’ gene
partner and green indicates the 3’ gene partner. For both the 5’ and 3’ gene partner,
fusion gene breakpoints can occur in the following genomic regions: 5’ untranslated
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region (5’UTR, triangle), coding sequence (CDS, rectangle), 3’UTR (circle), and
noncoding region (rounded rectangle). For each fusion event, a dotted line connects the
breakpoints in the 5’ and 3’ gene partners to create the predicted fusion and the circle
size, while number represents the total fusion events classified into the associated fusion
category.
(C) The dot plot shows the frequency of recurrent fusions found in each cancer type. The
most recurrent fusion in each cancer type is labeled. Cancer types without recurrent
fusions are not shown.
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Figure 3.2 Fusion expression outliers

(A) The dot plot indicates the percentage of fusions called in which one of the partner genes is
an expression outlier (overexpression or underexpression). The size of the dot corresponds
to the number of fusions called in each cancer type. Color corresponds to genes of interest
coming from lists of oncogenes, protein kinases, and tumor suppressor genes.
(B) The dot plot shows the relative expression level of samples with fusions compared to those
without fusions. Each sample has a particular expression percentile at a given gene, and
color indicates the median percentile of samples with a fusion in that gene. Genes are the
fifteen most recurrent oncogenes and tumor suppressor genes. Size corresponds to the
number of samples in each cancer type with a fusion at that gene.
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(C) Expression of samples at RET in thyroid carcinoma (THCA). Color indicates a categorical
copy number ranging from deep deletion to high amplification.
(D) Expression of samples at CBFB in acute myeloid leukemia (LAML). Color indicates a
categorical copy number ranging from deep deletion to high amplification.
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Figure 3.3 Protein kinase fusions.

(A) The bar chart indicates the number of protein kinase fusions with the kinase at the 5’ or
3’ end, inframe or frameshift, and kinase domain intact or disrupted.
(B) The left bar plot shows the percentage of samples with kinase fusions across different
cancer types. The number of samples with a kinase fusion is also indicated at the end of
each bar. 5’ kinase and 3’ kinase fusions are marked in light green and blue, respectively.
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The right bar plot shows the normalized percentage of kinase fusions broken down by
kinase groups.
(C) The dot plot shows the numbers of samples for recurrent fusions across different cancer
types. 5’ kinase and 3’ kinase fusions are marked in light green and blue, respectively.
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(D)

Figure 3.4 Kinase gene expression regulated by fusion

(A) The scatterplot shows the gene expression quantile (y-axis) for the 5’-kinase without copy
number variation (between 1 and 3 copies, x-axis). All genes are classified among three
categories: kinase expression higher, equal, and lower, as compared to partner expression,
marked in blue, grey, and red, respectively. The density plot for expression quantile is
also shown on the right panel.
(B) The scatterplot shows the gene expression quantile (y-axis) for the 3’-kinase without copy
number variation (between 1 and 3 copies, x-axis). The colors represent the same three
categories as (A). The density plot for expression quantile is also shown.
(C) Boxplot comparing the distribution of kinase gene expression quantile between the three
groups defined in (A) for 5’-kinase and 3’-kinase, respectively.
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(D) Schematic of TBABD--DDR2 fusion gene structure in a HNSC sample, and scatter plot of
DDR2 copy number versus mRNA expression in HNSC. The samples with and without
this fusion are marked in red and blue, respectively.
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Figure 3.5 Mutual exclusivity between driver mutations and driver fusions.

(A) The bar plot shows the percentages of samples with driver mutations only (green),
mutations only (orange), driver mutation and fusion (blue), mutation and fusion (pink), or
fusion only (light green) events in 299 cancer driver genes.
(B) Distribution of mutation burden across each alteration group designated in all figures.
(C) All samples with fusions or mutations in any of the genes indicated on the left are
displayed on the x-axis. For each gene, samples are clustered by the alteration group.
Bottom bar indicates cancer type.
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Figure 3.6 Druggable fusion targets.

(A) The bar chart indicates the number of samples potentially treatable based on their fusion
status.
(B) Percentages of LUAD samples with known smoking status.
(C) ESR1 domains kept in ESR1 fusions across cancer types.
(D) ALK expression across cancer types indicating ALK fusion status.
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Chapter 4: Integrative multi-omic profiling
reveals tumorigenic DNA methylation
associated with therapeutic vulnerability
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4.1

Abstract

Gene DNA methylation is frequently dysregulated in human cancers, however such
consequential deregulations are usually undelineated because they are inextricably linked with
other neutral alterations during tumor development. Here, we quantify multi-omic interactions of
506 CPTAC tumors from kidney, brain, lung, head and neck, and endometrium, to identify
aberrant methylation associated with RNA and protein abundance changes. Beyond the
conventional genetic studies, we uncover cancer-specific epigenetic drivers such as
hypomethylated FGFR2 in endometrial cancer. Tumors exhibiting hypermethylated STAT5A are
associated with pervasive regulome downregulation and immune cells depletions, suggesting
epigenetic silencing of STAT5A is a molecular switch that can be targeted to prevent
immunosuppression. Finally, we demonstrate that methylation subtype-enrichment information
can explain intra-tumor heterogeneity and phenotypes. Overall, our study provides a landscape of
cis-acting DNA methylation associated with transcriptional and translational changes in tumors,
illuminating how epigenetic regulation can act upon molecular mechanisms to promote
tumorigenesis.

4.2

Highlights

1. Integrated omic profiling catalogs epigenomic aberrations associated with cistranscriptional and translational changes across five cancer types.
2. FGFR2 and EGFR hypomethylation are bona fide driver DNA methylation events.
3. STAT5A methylation may serve as an epigenetic switch for tumor immune response in
HNSCC.
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4. Methylation subtype-enriched RNA and protein signatures provide insights into tumor
phenotypes and tumor heterogeneity.

4.3

Introduction

Methylation of cytosines is an epigenetic modification adding information onto DNA
without changing the genetic sequence, conferring stability and flexibility in spatiotemporal gene
regulation of many biological processes. Aberrant DNA methylation is a hallmark of the
development and progression of human cancers1–3, which has primarily been observed in the
global hypomethylation of mostly repetitive sequences and gene-specific hypermethylation of
numerous CpG islands (CGI)4,5. Epigenetic modifications within promoter regions can alter the
expression of proximal genes, leading to transcriptional silencing of tumor suppressor genes or a
loss of regulation of oncogenes. The widespread and pervasive changes in the patterns of DNA
methylation arise in the early stages of cancer formation6. Given the reversible and dynamic nature
of DNA methylation, treating cells with DNA demethylating agents can reprogram neoplastic cells
toward a normal state7. Delineating the functional consequences of aberrant DNA methylation is
critical for improving cancer diagnosis, prognosis, and treatment.
Despite the growing number of genome-wide methylation studies across various cancer
types, it remains challenging to distinguish the relatively small number of functional DNA
methylations that are responsible for the development and progression of cancer from the large
number of co-occurring neutral methylations8. Various systematic analytical approaches have been
developed to explore the connection between DNA methylation and tumorigenic outcomes by
integrating multi-omic data9,10. However, studies exploring the downstream effects of aberrant
DNA methylation have largely relied on tumor RNA expression without corresponding adjacent
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normal samples. We aimed to define the extent to which information contributed by DNA
methylation is transcribed to RNA expression, translated to protein abundance, and how this may
lead to various tumor outcomes. Since proteomic data provides a direct measure of biological
activity, profiling the functional changes of DNA methylation directly from transcriptomic and
then proteomic data could complement each other, enhance interpretation of driver aberrations,
and provide clinically relevant information.
Here, we investigate aberrant DNA methylation associated with transcriptional and
translational changes using multi-omics resources from the Clinical Proteomic Tumor Analysis
Consortium (CPTAC)11. By combining DNA methylation, RNA expression, and proteomic data
from 506 patients across five cancer types, we can systematically elucidate the information flow,
characteristics, and functional impacts of cis-acting aberrant DNA methylation in tumorigenesis
for the first time. Our study provides a comprehensive catalogue of putative DNA methylation
events with specific functional consequences, highlighting key changes to driver genes that affect
cancer hallmark pathways in a coordinated manner. We also reveal distinct methylation subtypes
among cancer types and compile a set of RNA and protein signatures that closely reflect the
molecular features associated with each subtype. Finally, we pinpoint the clinically-actionable
genes regulated by DNA methylation, which is critical for finding subtype-specific diagnosis and
treatment strategies. The extensive functional catalogue established in this study of human DNA
methylomes is an important step towards a deeper understanding of DNA methylation-mediated
tumorigenesis and tumor progression, offering new opportunities for epigenetic therapy.
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4.4

Results

4.4.1
Integrative multi-omic profiling empowers aberrant DNA
methylation discovery
To create a comprehensive functional landscape of cancer methylomes across cancer types,
we assembled 506 human tumors with available DNA methylation (Infinium EPIC array), gene
expression levels (RNA-seq), and protein abundance level (mass spectrometry), across five cancer
types from CPTAC including 107 clear cell renal cell carcinoma (ccRCC), 97 glioblastoma (GBM),
106 head and neck squamous cell carcinoma (HNSCC), 108 lung adenocarcinoma (LUAD), and
88 uterine corpus endometrial carcinoma (UCEC). For cohorts without DNA methylation data
from normal adjacent tissues, GBM and UCEC, we collected DNA methylome from The Cancer
Genome Atlas (TCGA) and the Therapeutically Applicable Research to Generate Effective
Treatments (TARGET) datasets (Table S1, Methods). These TCGA and TARGET datasets both
include DNA methylation data from corresponding normal adjacent tissues in the form of Infinium
HumanMethylation BeadChip (HM450), giving us an opportunity to estimate the methylation
variance among reference DNA methylation data and thus to test the association in tissue-specific
context with negligible batch effects (Figure S1).
We detected recurrent and deregulated DNA methylation in tumors compared to adjacent
normal tissues, and tested the association between DNA methylation and mRNA expression
change or protein abundance change separately using RESET10. Our analysis aimed to profile the
aberrant DNA methylation for regions actively contributing to gene regulation12 thereby limiting
the probe sets to those within promoter regions (Figure S1). Overall, we detected 2,236
hypermethylated CpG sites associated with mRNA downregulation of 978 genes, and 895 CpG
sites with protein downregulation of 434 genes; while 333 hypomethylated CpG sites are
associated with mRNA upregulation of 256 genes, and 176 with protein upregulation of 137 genes
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(FDR < 10%, Figure 1A). Consistent with previous studies, DNA hypermethylation is more
frequent than hypomethylation events in all cancer types10,13. Our results confirmed several classic
epigenetically-regulated genes in tumors, including MLH114, MGMT15, WIF116, CASP817, HIC118,
and GSTP119. However, the vast majority of identified genes had not been previously implicated
in DNA methylation-mediated regulation (Table S1).
Next, we examined the concordance between mRNA and protein changes of individual
aberrant DNA methylation events. Out of 1,051 hypermethylated genes and 225 hypomethylated
genes with both mRNA and protein abundance data, we identified 387 hypermethylated genes and
83 hypomethylated genes associated with both RNA expression and protein abundance changes
(Figure 1B). Overall changes were moderately or strongly correlated across cancer types
(Spearman’s rho ranging from 0.30 to 0.82, Spearman’s P value < 0.001; Figure 1C, Figure S1),
suggesting transcriptional and translational changes from the same aberrant DNA methylation are
comparable between the two separate association tests. Genes with a negative correlation between
transcript and protein abundance may be attributed to biological factors such as translational
regulation, tissue-specific expression, and mRNA degradation or technical factors due to lowabundance proteins or transcripts 20,21.
Having identified a comprehensive map of cis-acting cancer methylome, we were able to
delineate the functional impacts of those deregulated DNA methylations on cancer cell
development in a set of genes directly related to tumorigenesis (Table S2). Figure 1D illustrates
the median expression and methylation differences between samples with or without aberrant
DNA methylation in cancer-associated genes. In line with previous studies, we observed 43 of the
aberrations are cancer type-specific events13,19,22, such as tumor necrosis receptor FAS in GBM23
and homeobox genes associated transcription factor HNF1B in UCEC24, highlighting the context72

dependent complexity of DNA methylation regulation and tissue-specific carcinogenesis13.
Conversely, only 3 of them are common events across cancer types, including hypomethylated
TRIP10, MGMT, and STAT5A. The recurrence of those aberrant DNA methylation patterns across
cancer types suggests their importance in cancer cell development.

4.4.2
cis-acting aberrant DNA methylation on driver genes can be
tumorigenic
We reasoned that DNA methylation modulating driver gene expression could be important
in cancer progression, so we characterized cis-acting aberrant DNA methylation on 299 driver
genes25 to understand the nature of tumorigenic DNA methylation. Since DNA methylation can
affect the binding of transcription factors and vice versa26, we examined the number and
enrichment of transcription factor binding sites (TFBS) in loci associated with expression changes.
All the loci are associated with at least one TFBS, and hypomethylated CGI sites were
characterized by a higher number of TFBS (mean 25.1 TFBS) than hypermethylated CGI sites
(mean 15.8 TFBS) (Figure 2A). STAT5A and HIF1B, which are both master regulators involved
in tumorigenesis in various cancer types, were the most enriched TFBS in hypermethylated and
hypomethylated loci, respectively. The results support the notion that transcription factors might
be the readers and effectors of aberrant DNA methylation26, leading to altered expression as
revealed by transcriptomic and proteomic data.

Next, we wanted to explore the relationship between genetic alterations and DNA
methylation for each gene and cancer type. Of the 7 driver genes with cis-acting DNA methylations,
most of the methylations were mutually exclusive with genomic alterations as shown in Figure 2B.
For example, the correlation between B2M expressions and B2M promoter DNA methylation
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suggests methylation is the main factor regulating its expression (Figure 2C). Our results suggest
aberrant DNA methylation resulting in functional changes undergoes positive selection and thus
likely sufficient to promote tumorigenesis.
Interestingly, DNA hypomethylation is the main perturbation occurring in the IDH2 gene
and was found in 7.9% (17 of 215 tumors) of the total tumors in ccRCC (n=13) and LUAD (n=4).
Promoter DNA methylation is strongly correlated with IDH2 expression (Figure 2D). Since
overexpression of IDH2 contributes to altering energy metabolism27,28, we examined the IDH2related cancer metabolism activities between samples with and without IDH2 hypomethylation.
The results suggest a general upregulation of metabolic gene expression including KDMs, ALKBHs,
TETs, and MTOR, while the genes and extent vary slightly by cancer types (Figure 2D). Also, we
detected a compelling enrichment of samples with hypomethylated IDH2 in metabolic processes
directly associated with tumor development (Hypergeometric P < 0.05, Figure S2). IDH2
hypomethylation is consistently correlated with upregulation of MTOR across cancer types,
suggesting its prevalent oncogenic function through MTOR pathway activation.

4.4.3

Hypomethylated RTKs are newly identified driver events

We found that several receptor tyrosine kinases (RTKs) (e.g. FGFR2 and EGFR) are
frequently hypomethylated across cancer types (Figure 1D). To better dissect the contribution of
hypomethylated RTKs to oncogene activation, we systematically examined promoter methylation
and genetic alterations, including mutations, fusions, and CNVs, and their effects on RTKs RNA
and protein levels.
While 66.7% (12 of 18 mutations) identified FGFR2 missense and indel mutations were
activating mutations that enabled high-grade inflammation and cell proliferation 29–34(Figure 3A),
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we discovered 7 UCEC tumors carrying cis-acting hypomethylated FGFR2, 5 of which had cooccuring genomic alterations. Unsupervised clustering of DNA methylation data across 101
CPTAC UCEC tumors and 43 TCGA normal samples revealed that FGFR2 hypomethylated cases
form a distinct cluster with lower DNA methylation than normal cases (Figure 3B). Specifically,
one CGI (cg10314760) within the FGFR2 promoter displayed a strong correlation between
promoter hypomethylation and active gene expression both at RNA and protein levels (Figure 3C).
Our results suggest that promoter methylation is a major factor modulating FGFR2 expression and
FGFR2 hypomethylation represents another main mechanism of RTK activation comparable to
activating mutations.
To separate the oncogenic effects of FGFR2 hypomethylation from co-occurring
aberrations, we stratified UCEC tumors by the FGFR2 genomic alteration status and examined
FGFR2 expression within each stratum. We found that tumors with FGFR2 hypomethylation are
correlated with FGFR2 upregulation in each stratum (Figure 3D). The result not only reveals the
dominant gain-of-function role of promoter hypomethylation, but also suggests that whereas
activating mutations, amplifications, and promoter hypomethylation enable FGFR2 upregulation
to different extents, co-occurring FGFR2 hypomethylations result in similar, even more profound,
expression changes than either genomic alteration alone.
Similarly, Hypomethylated EGFR is associated with EGFR upregulation in GBM (Figure
S3). Overall, although recurrent gain-of-function genomic alterations in RTKs have long been
known to promote a variety of cancers35, our results reveal that RTK hypomethylation is a bona
fine epigenetic driver across multiple cancer types.
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4.4.4
Transcription factor STAT5A hypermethylation is associated with
pervasive changes in STAT5A regulome activity
Altered expression of a single transcription factor (TF) usually disrupts downstream
regulome activity, the interplay between TF and its products, and leads to neoplastic
transformation36. Therefore, to identify deregulated TF genes modulated by promoter methylation
in tumors, we tested the association between TFs with cis-acting aberrant DNA methylation and
their regulome gene expression changes at both RNA and protein levels.
STAT5A controls a wide range of cellular processes such as cell identity, cytotoxicity, and
cell survival; dysregulation of those pathways contributes to tumorigenesis37. Unsupervised
clustering of STAT5A-interacting gene expression data from 101 HNSCC tumors divided samples
into two groups: those with high regulome activity, and those with low regulome activity (Figure
4A). Notably, samples with hypermethylated STAT5A were significantly enriched in the regulomelow group (Fisher’s exact test, P=0.001). The same pattern was observed in protein abundance
(Figure 4B, Fisher’s exact test, P=0.028). The enrichments were not correlated with tumor purity
(Figure S4). Exome sequencing of these tumors did not identify any distinct, recurrent coding
sequence mutations in STAT5A-interacting genes (Table S3), suggesting additional genetic drivers
were not involved. STAT5A phosphorylation is not significantly associated with either STAT5A
methylation status or STAT5A regulome activity (Figure S4). The enrichments we observed may
indicate STAT5A is aberrantly methylated in HNSCC tumors and may subsequently lead to
pervasive regulome changes.
To delineate the contribution of aberrantly methylated STAT5A to downstream regulome
changes, we compared HNSCC tumors by STAT5A methylation status. Since samples with
hypermethylated STAT5A are associated with lower regulome activity both at RNA and protein
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levels (Figure 4C), we hypothesized that STAT5A-interacting components would be
downregulated in samples with hypermethylated STAT5A, including receptors, kinases, repressors,
co-activators, and target genes (Figure 4D). Among the target genes, we observed significant
downregulation of IRF1, PRF1, IFNG, IL2RA, and IL6ST (Wilcoxon P<0.05) both at RNA and
protein levels, suggesting a direct regulatory role of hypermethylated STAT5A in cytokine
production, cytotoxicity, cell proliferation, and interferon signaling. Similar to HNSCC tumors,
samples with hypermethylated STAT5A are associated with low regulome activity in ccRCC tumor
(Figure S4). In line with our previous finding that STAT5A binding motif is enriched within driver
genes with aberrant DNA methylation (Figure 2A), our results suggest STAT5A plays an important
role in DNA methylation-mediated tumorigenesis.

4.4.5
Hypermethylated STAT5A is associated with immune cells
depletion in HNSCC
STAT5A signaling represents a critical signaling pathway in the pathogenesis of human
cancers. Recent data have shown that STAT5A-mediated interferon signaling regulates the
expression of PD-L1 and PD-L2, reflecting the clinical significance of STAT5A signaling in
immunotherapy38. The lowly expressed STAT5A target genes from our analysis are directly
implicated in immune response, such as IL2RA, IRF1, and IFNG, which cooperate to maintain
normal immune function and homeostasis39. Thus, we focused on characterizing the immune
component of HNSCC tumors to understand how hypermethylated STAT5A affects the tumor
microenvironment.
To construct the microenvironment of HNSCC tumors, we deconvoluted cell mixtures into
multiple immune cell types from transcriptome data by using xCell40. Consensus clustering of
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thirty different immune-related cell types identified three major immune clusters, and STAT5A
hypermethylated samples were significantly enriched in one of the immune subtypes (Fisher’s
exact test, P=0.002) (Figure 5A). Interestingly, the Immune Subtype 2 of HNSCC had significantly
lowest xCell immune score (Figure 5B, Wilcoxon P < 0.01) and was enriched with late-stage
tumors (Figure 5A, top panel, Fisher’s exact test, P=0.007). Deconvolution of tissue-infiltrating
immune and stromal populations revealed that samples with hypermethylated STAT5A had limited
numbers of CD4+ and CD8+ T cells, macrophages, dendritic cells, and stroma cells relative to
samples with normal methylated STAT5A. In line with the enrichment of samples with
hypermethylated STAT5A in the immune-low group, STAT5A hypermethylated samples, which
adjusted for tumor purity, displayed lower immune scores (Figure 5B), decreased expression of
genes associated with immune effectors and dendritic cells at both gene and protein levels (Figure
5C and 5D).
Our finding of lower tumor microenvironment factors in STAT5A-hypermethylated
samples is consistent with previous studies in which hematopoietic stem cell proliferation was
severely impaired in the Stat5A-deficient mice41–43. Epigenetically silenced STAT5A has been
identified as a key tumor suppressor in lymphoma cancer cell lines, contrasting to the role of its
closely related paralog, STAT5B, in malignant transformation44. In addition, studies have indicated
that the development of HNSCC is closely related to immunosuppression and immune escape45,
suggesting that STAT5A hypermethylation might be a mechanism to mediate the disease dependent
specificity of STAT5A among STATs family46, where the alteration disallow access to distinct
panels of genes involved in tumor immunogenicity.
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4.4.6
cancer

Aberrant methylation associated with therapeutic vulnerability in

Understanding the global methylation patterns for various tumors helps tailor treatment to
specific tumor subtypes. To identify subtypes based on methylation patterns, we used uniform
manifold approximation and projection (UMAP) to reduce methylation signals from 340,000 CGIs
into two dimensions47. Cancers form well-separated clusters by the organ system, such as brain
(GBM), kidney (ccRCC), lung (LUAD), head and neck (HNSCC), and uterus (UCEC) (Figure
6A). The results suggest that the UMAP projection of DNA methylation data reflects cell-of-origin
faithfully.
Next, we took CGIs showing significant difference between tumor samples and normal
tissues, then performed unsupervised classification of tumors within each cancer type using
consensus clustering on the most variable 8,000 CGIs. We identified between 2 and 6 clusters from
each cancer type, and re-colored the UMAP projection according to our subtype classifications
(Figure 6A, third panel). The methylation subtype result captured several important clinical
characteristics. For example, UCEC subtype C3 is enriched with tumors displayed high frequency
microsatellite instability and has higher mean MSIsensor score compared to other UCEC groups
(Figure S6). The GBM subtype C6 features CpG island methylator phenotype associated with
IDH1 mutation23. Our result suggests that clustering of cancer samples based on variable DNA
methylation can lead to identification of molecularly and clinically relevant subtypes.
To further explore the biological differences between methylation subtypes, we performed
over-representation pathway analysis using differentially expressed genes and proteins in each of
the per-cancer methylation subtypes (Figure 6B and Table S4, Hypergeometric P < 0.05).
Significant subtype-specific tumorigenic signatures were consistently observed at the
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transcriptomic and proteomic level, such as UCEC-C2 being enriched for NOTCH signaling, and
LUAD-C2 with RNA metabolism48,49. Despite having very different cancer type compositions,
HNSCC-C1 and GBM-C3 were characterized by immune-related signatures both at RNA and
protein levels, and were strongly associated with the immune-high groups identified by cell-type
enrichment score (Fisher’s exact test, P < 0.001). The correlation suggests signaling convergence
among various cancers, in line with the previous studies that some methylation subtypes are
significantly associated with immune signature49–51. We also identified four druggable genes that
are significantly overexpressed within specific methylation subtypes compared to the other
subtypes from each cancer type (Figure S6 and Table S5, Wilcoxon P < 0.005). The results not
only demonstrate the heterogeneity within cancer types, but also provide the new clues for
understanding how distinct methylation patterns may lead to various cancer phenotypes across
cancer types.
Finally, we investigated potentially druggable targets with cis-acting deregulated DNA
methylation, which may confer a therapeutic vulnerability to drugs targeting aberrant gene
expression (Table S6). We integrated cis-acting DNA methylation with the Clinical Interpretation
of Variants in Cancer (CIViC)52, prioritizing for target genes with outlier expression for which
pharmacological intervention might be avaliable. Allowing for “off-label” drug treatment, we
found 31.6% of samples (160 of 506 tumors) likely to benefit from one or more treatments
targeting genes altered by DNA methylation (Figure 6C). The most frequent druggable DNA
methylation events across the five cancer types are those on EGFR (number of tumors = 55),
NAPRT (n=52), and MGMT (n=33). Tumor-specific loss of NAPRT mediated by promoter
hypermethylation is synthetically lethal with NAMPT inhibitor treatment in multiple cancer types,
resulting in inactivations of nicotinic acid salvage pathways53. Collectively, the characterization
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of cis-acting aberrant DNA methylation and cancer methylome reveals potential new directions
for treatment optimization.

4.5

Discussion

Our multi-omics analysis of 506 tumors greatly boosts our ability to identify functional
impacts of epigenetic changes in tumors, providing unprecedented insights into both cancer typespecific and common cis-acting DNA methylation and methylation-based stratification of cancer
patients. Based on genome-wide DNA methylation patterns, we identified and characterized
twenty methylation subtypes enriched with various RNA and protein signatures showing potential
therapeutic and prognostic implications for cancer management. Of these, one multi-cancer group
consists of different cancer types enriched with a convergent immune-related signature. Therefore,
the cancer methylome might be an important factor in determining the efficacy of potential
immunotherapies. We observed significantly elevated expression levels of putative drug targets in
four methylation subtypes including two LUAD subtypes and two GBM subtypes (Figure 6B),
implying that the differential expression of target genes is related to distinct methylation patterns.
Moreover, we observed clinically-relevant alterations with important therapeutic potential in 160
out of 506 tumors. Targeting those common aberrant methylation events could broaden the
therapeutic reach of existing drugs by including more patients and a broader range of tumor types.
To maximize this benefit, future studies optimizing epigenetic therapies should be performed.

We uncovered several bona fide DNA methylation drivers with functional consequences,
such as hypomethylated FGFR2 and EGFR (Figure 3 and Figure S3). Excluding mutations and
copy number variations in FGFR2, 7 out of 95 (7.4%) of UCEC tumors harbored hypomethylated
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FGFR2, which could expand conventional genotype-directed clinical trials. In addition, the
apparent co-occurrence of FGFR2 hypomethylation and genomic alterations within the same
tumors suggests an selective advantage to development of a second FGFR2 alteration, perhaps
from enhanced FGFR2 signaling in these cells. It is also possible that the genomic alterations
disrupt the reading, writing, or maintaining of DNA methylation machinery in tumor cells,
subsequently leading to an aberrant decrease of methylation within the FGFR2 promoter. However,
since our result shows UCEC tumors harboring epigenetic and genetic alterations are significantly
associated with FGFR2 upregulation, it is likely that FGFR2 hypomethylation works in concert
with other genomic alterations at FGFR2 to promote tumorigenesis.
Studies have shown HNSCC tumors evade the host immune system by manipulating their
own immunogenicity45, suggesting that STAT5A hypermethylation uncovered in our study is a
novel mechanism to promote immunosuppression. Furthermore, our findings reinforce the critical
nature of STAT5A as a signaling hub in modulating tumor immunogenicity, shaping immune
response, and orchestrating immune cell differentiation across multiple cancers, and may suggest
opportunities for therapeutic intervention through reversing epigenetic alterations within the
STAT5A promoter. DNMT inhibitors such as 5’-aza have been shown to reduce methylation of
STAT5A promoter in cell lines44, and was an FDA-approved therapy in treating myelodysplastic
syndrome54. Furthermore, activation of STAT5A signaling may transform an immunologically
cold, or inactive, tumor into a hot, inflamed tumor and thus increase anti-tumor immune response.
Understanding the full extent of mechanisms responsible for the effect of STAT5A
hypermethylation on the immune-related signaling pathways, the interaction between them, and
the impact on therapeutic sensitivity requires additional investigation.
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Overall, our results help deconvolute the contribution of DNA methylation in
tumorigenesis and delineate what roles it has in initiating and maintaining malignancies. This deep
characterization of cis-acting events and cancer methylome will inform functional explorations of
aberrant DNA methylation in a systematic way, revealing potential new disease mechanisms and
therapeutic opportunities.

4.6

STAR Methods

4.6.1 CPTAC datasets description
We aggregated somatic variants, copy number variations, transcriptomic and proteomic
data generated by the National Cancer Institute CPTAC from CPTAC data portal, Genomic Data
Commons (GDC), and published studies (See Data and Code Availability). The datasets includes
CPTAC Clear Cell Renal Cell Carcinoma (ccRCC) Discovery Study55, CPTAC Glioblastoma
(GBM) Discovery Study, CPTAC Lung Adenocarcinoma (LUAD) Discovery Study56, CPTAC
Head and Neck Cancer (HNSCC) Discovery Study, and CPTAC Uterine Corpus Endometrial
Carcinoma (UCEC) Discovery Study57.
Generally, all the whole exome sequencing and RNA sequencing data was harmonized by
National Cancer Institute Genomic Data Commons (GDC) https://gdc.cancer.gov/about-data/gdcdata-harmonization, which included alignment to GDC’s hg38 human reference genome
(GRCh38.d1.vd1) and additional quality checks. Somatic mutations were called by the
SomaticWrapper pipeline, which includes four different callers: Strelka258, MUTECT v1.1.759,
VarScan v.2.3.860, and Pindel v.0.2.561. Gene fusions in RNA-Seq samples were called using three
callers: STAR-Fusion, EricScript, and Integrate, with fusions reported by at least 2 callers or
reported by STAR-Fusion being retained62. For transcriptomic data, We obtained the gene-level
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read count, Fragments Per Kilobase of transcript per Million mapped reads (FPKM), and FPKM
Upper Quartile (FPKM-UQ) values by following the GDC’s RNA-Seq pipeline (Expression
mRNA

Pipeline)

https://docs.gdc.cancer.gov/Data/Bioinformatics_Pipelines/Expression_mRNA_Pipeline/, except
running the quantification tools in the stranded mode. We used HTSeq v0.11.263 to calculate the
gene-level stranded read count (parameters: -r pos -f bam -a 10 -s reverse -t exon -i gene_id -m
intersection-nonempty --nonunique=none) using GENCODE v22 (Ensembl v79) annotation
downloaded from GDC (gencode.gene.info.v22.tsv). The read count was then converted to FPKM
and FPKM-UQ using the same formula described in GDC’s Expression mRNA Pipeline
documentation. The peptide search database of those cohorts is RefSeq 20180629. To facilitate the
cross-data interpretation, we improved the annotation of the proteomic databases by recovering
HGNC

Gene

IDs

from

NCBI/Entrez

Gene

IDs

using

HGNC

BioMart

(https://biomart.genenames.org/) and retrieving the UniParc IDs and checksums for all the protein
sequence in all databases (DOI: 10.1093/bioinformatics/bth191). Note that we keep the gene
symbols identical to the RefSeq records at the time of download.

4.6.2 DNA methylation data preprocessing
Raw methylation image files generated by Illumina Infinium EPIC BeadChip were
downloaded from the CPTAC GDC (See Data Availability). We calculated and analyzed
methylated(M) and unmethylated (U) intensities for tumor and normal adjacent tissue samples as
described previously64. We flagged locus as NA where probes did not meet a detection p-value of
0.01. Probes with MAF more than 0.1 were removed, and samples with more than 85% NA values
were removed. Resulting beta values of methylation were utilized for subsequent analysis.
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The raw methylation image files of TARGET-NBL, TCGA-GBM, and TCGA-UCEC
datasets generated by Illumina Infinium HumanMethylation450 BeadChip assays, used here for
normal

adjacent

tissue

approximation,

(https://gdac.broadinstitute.org/)

were

or

downloaded

from

TARGET

TCGA
data

FireHose
matrix

(https://ocg.cancer.gov/programs/target/data-matrix) and processed as aforementioned steps.

4.6.3 Defining aberrant DNA methylation using RESET
We mapped CpG probes to canonical transcriptional start sites and unconventional exonic
TSS as defined by FANTOM5 consortium65, and then applied RESET algorithm10 separately on
each tumor type using the corresponding adjacent normal tissue samples. For identifying aberrant
DNA methylation events associated with transcriptional or translational changes, aggregated
mRNA expression and global proteome data were used as an input, respectively. We considered
the association as significant only events with a false discovery rate FDR < 10% and a RESET
score > 1.

4.6.4 Defining cancer-associated genes
Cancer-associated genes were compiled from genes defined by Bailey et al.25 and cancerassociated genes listed in Mertins et. al66 and adapted from Vogelstein et al.67.

4.6.5 Cell type enrichment deconvolution using gene expression
We used the FPKM-UQ expression matrix as the input, and the abundance of each cell
type was inferred by the xCell web tool40. xCell is a gene signatures-based method learned from
thousands of pure cell types from various sources, which performed the cell type enrichment
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analysis from gene expression data for 64 immune and stromal cell types (default xCell signature).
xCell generated an immune score per sample that integrates the enrichment scores B cells, CD4+
T-cells, CD8+ T-cells, DC, eosinophils, macrophages, monocytes, mast cells, neutrophils, and NK
cells; a micro-environment score which was the sum of the immune score and stroma score.

4.6.6 Immune clustering using cell type enrichment scores
We used the FPKM-UQ expression matrix as the input, and the abundance of each cell
type was inferred by the xCell web tool40. xCell is a gene signatures-based method learned from
thousands of pure cell types from various sources, which performed the cell type enrichment
analysis from gene expression data for 64 immune and stromal cell types (default xCell signature).
xCell generated an immune score per sample that integrates the enrichment scores B cells, CD4+
T-cells, CD8+ T-cells, DC, eosinophils, macrophages, monocytes, mast cells, neutrophils, and NK
cells; a micro-environment score which was the sum of the immune score and stroma score.
Immune subtypes of each of HNSCC tumors were generated based on the consensus
clustering68 of the cell type enrichment scores by xCell. Among the 64 cell types tested in xCell,
we selected immune-related cell types. We performed consensus immune clustering based on the
z-score normalized xCell enrichment scores. The consensus clustering was determined by the R
package ConsensusClusterPlus(parameters: reps = 2000, pItem = 0.9, pFeature = 0.9, clusterAlg
= "kmdist", distance = "spearman").

4.6.7 Pathway over-representation analysis
To designate the representative pathways of methylation subtypes from transcriptomic and
proteomic data, we used the Wilcoxon rank sum test to select the top 250 differentially expressed
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features (mRNA and proteins) for each subtype. We then performed hierarchical clustering on
these features. Each set of clustered features underwent pathway enrichment analysis using
Reactome69. Pathways with p-value smaller than 0.05 were manually reviewed and highlighted in
Figure 6B.

4.6.8 Identification of druggable gene with aberrant methylation
CIViC is a curated list of druggable variants describing their therapeutic, prognostic,
diagnostic and predisposing relevance. We downloaded the list and intercept with the list of genes
with aberrant methylation. The potential druggability of each gene was manually reviewed to see
if the altered expression of such gene is associated with therapeutic relevance supported by
literature.
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4.7 Figures

Chapter 4
Figure 4.1 The cancer methylome landscape associated with transcriptomic and proteomic change

(A) Significance of aberrant methylation associated with transcriptomic (upper) and
proteomic (lower) changes. The statistical significance (false discovery rate (FDR)<0.1)
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and median difference of expression between aberrant and normal samples are displayed
in volcano plot. Representative genes are colored based on methylation status: yellow,
hypermethylation; blue, hypomethylation. Dot size indicates the number of CGIs
associated with expression changes.
(B) Venn diagrams of the number of genes with hypermethylation (upper) and
hypomethylation (lower) having significant transcriptomic and/or proteomic changes.
(C) Correlation between RNA expression and protein abundance of hypermethylation (blue),
normal methylation (grey), and hypomethylation (yellow).
(D) Common and cancer type-specific aberrant methylations. The mean methylation values
difference (upper), RNA difference (middle), and protein difference (lower) between
aberrant and normal samples at significant CpG sites are indicated by shading of the
filled circle. The methylation difference is derived from the mean beta values
differences between samples with or without aberrant methylation. For RNA and protein
differences, the values are derived from the mean differences of scaled RNA sequencing
data or proteomic data between samples with or without aberrant methylation.
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Figure 4.2 Characterization of aberrant methylation in driver genes

(A) The Distribution of the number of transcription factor binding sites for functional
hypermethylation (yellow) and hypomethylation (blue).
(B) Mutual exclusivity and co-occurrence of genomic and epigenomic alterations in driver
genes in different cancer types. Each column represents a different tumor.
(C) Example of correlations between promoter methylation and gene expression (upper) and
protein abundance (lower) in selected driver genes. Samples are colored based on genetic
and/or epigenetic alterations of the gene.
(D) Correlations between promoter methylation and gene expression (upper) and protein
abundance (lower) in IDH2. Pathway diagram representing the mean expression difference
between IDH2 hypomethylated samples and normal methylated samples as indicated by
shading of the filled squares.
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Figure 4.3 Collaborative effects of FGFR2 mutations and hypomethylation on FGFR2 upregulation

(A) Lolliplot showing somatic mutations of FGFR2 in UCEC samples. The amino acids and
types of mutations are labelled. Positions which are recurrently mutated are highlighted
with the number of occurrences. The FGFR2 functional domains are colored. Ig:
Immunoglobulin.
(B) DNA methylation of the FGFR2 promoter in UCEC tumors (upper) and normal adjacent
tissues (lower).
(C) Correlation between methylation at significant CpG sites and gene expression (upper) and
protein abundance (lower). Samples are colored based on genetic and/or epigenetic
alterations of FGFR2. Tumors harboring FGFR2 hypomethylation are highlighted by large
dot size.
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(D) Effect of FGFR2 hypomethylation on RNA and protein levels stratified by FGFR2
genomic alterations. Tumors harboring FGFR2 hypomethylation are highlighted by large
dot size.
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Figure 4.4 STAT5A hypermethylation associated with pervasive STAT5A regulome changes

(A) Unsupervised clustering of STAT5A regulome genes using Pearson correlation of scaled
RNA sequencing data and annotated with STAT5A expression and methylation levels.
Mean activity indicates the overall sum of regulome activity.
(B) Unsupervised clustering of STAT5A regulome genes using Pearson correlation of scaled
global proteome data.
(C) Violin plot showing samples with hypermethylated STAT5A have lower regulome activity
than the samples with normal methylated STAT5A.
(D) Pathway members and interactions in the STAT5A regulome. The mean expression
differences between STAT5A hypermethylated samples and normal methylated samples
are indicated by shading of the filled squares.
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Figure 4.5 Functional impact of STAT5A hypermethylation on HNSCC tumor immunosuppression.

(A) Distinct immune subtypes of HNSCC tumors identified by consensus clustering of 106
HNSCC tumors using xCell enrichment scores. Top panel shows the immune score, DNA
methylation status of STAT5A, immune subtype, and tumor stage. The heatmap shows the
xCell enrichment scores deconvoluted from RNA-seq data.
(B) Violin plot showing samples with hypermethylated STAT5A are enriched in Immune
Subtype 2 and have decreased immune score.
(C) Violin plot showing samples with hypermethylated STAT5A have decreased expression of
immune effectors.
(D) Violin plot showing samples with hypermethylated STAT5A have decreased expression of
dendritic cells.
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Figure 4.6 Summary of the cancer methylome for tumor signatures and therapy

(A) Projection of the 506 cancer methylomes using UMAP. Each point is a sample and is
colored based on the cancer type (left), sample type (middle), or methylation subtype
(right).
(B) Relationship of per-cancer methylation subtypes (upper), RNA expression signature
(middle), and protein signature (lower). Potentially druggable genes that are significantly
upregulated within subtypes are labeled in inset.
(C) Breakdown of potentially druggable genes whose expression is altered by tumorigenic
DNA methylation.

95

Reference
1.

Feinberg, A. P., Ohlsson, R. & Henikoff, S. The epigenetic progenitor origin of human
cancer. Nat. Rev. Genet. 7, 21–33 (2006).

2.

Shen, H. & Laird, P. W. Interplay between the cancer genome and epigenome. Cell 153,
38–55 (2013).

3.

Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome - biological and
translational implications. Nat. Rev. Cancer 11, 726–734 (2011).

4.

Ehrlich, M. DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400–
5413 (2002).

5.

Berman, B. P. et al. Regions of focal DNA hypermethylation and long-range
hypomethylation in colorectal cancer coincide with nuclear lamina--associated domains.
Nat. Genet. 44, 40 (2012).

6.

Easwaran, H., Tsai, H.-C. & Baylin, S. B. Cancer epigenetics: tumor heterogeneity,
plasticity of stem-like states, and drug resistance. Mol. Cell 54, 716–727 (2014).

7.

Ahuja, N., Sharma, A. R. & Baylin, S. B. Epigenetic Therapeutics: A New Weapon in the
War Against Cancer. Annu. Rev. Med. 67, 73–89 (2016).

8.

Kalari, S. & Pfeifer, G. P. Identification of driver and passenger DNA methylation in cancer
by epigenomic analysis. Adv. Genet. 70, 277–308 (2010).

9.

Fan, S. et al. Integrative analysis with expanded DNA methylation data reveals common
key regulators and pathways in cancers. NPJ Genom Med 4, 2 (2019).

10. Saghafinia, S., Mina, M., Riggi, N., Hanahan, D. & Ciriello, G. Pan-Cancer Landscape of
Aberrant DNA Methylation across Human Tumors. Cell Rep. 25, 1066-1080.e8 (2018).

96

11. Ellis, M. J. et al. Connecting genomic alterations to cancer biology with proteomics: the
NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discov. 3, 1108–1112 (2013).
12. Ziller, M. J. et al. Charting a dynamic DNA methylation landscape of the human genome.
Nature 500, 477–481 (2013).
13. Vidal, E. et al. A DNA methylation map of human cancer at single base-pair resolution.
Oncogene 36, 5648–5657 (2017).
14. Simpkins, S. B. et al. MLH1 promoter methylation and gene silencing is the primary cause
of microsatellite instability in sporadic endometrial cancers. Hum. Mol. Genet. 8, 661–666
(1999).
15. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma.
N. Engl. J. Med. 352, 997–1003 (2005).
16. Deng, X., Hou, C., Wang, H., Liang, T. & Zhu, L. Hypermethylation of WIF1 and its
inhibitory role in the tumor growth of endometrial adenocarcinoma. Mol. Med. Rep. 16,
7497–7503 (2017).
17. Gonzalez-Gomez, P. et al. Deletion and aberrant CpG island methylation of Caspase 8 gene
in medulloblastoma. Oncol. Rep. 12, 663–666 (2004).
18. Chen, W. Y. et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent
spectrum of malignant tumors. Nat. Genet. 33, 197–202 (2003).
19. Witte, T., Plass, C. & Gerhauser, C. Pan-cancer patterns of DNA methylation. Genome
Med. 6, 66 (2014).
20. Liu, Y., Beyer, A. & Aebersold, R. On the Dependency of Cellular Protein Levels on
mRNA Abundance. Cell 165, 535–550 (2016).

97

21. Buccitelli, C. & Selbach, M. mRNAs, proteins and the emerging principles of gene
expression control. Nat. Rev. Genet. (2020) doi:10.1038/s41576-020-0258-4.
22. Hansen, K. D. et al. Increased methylation variation in epigenetic domains across cancer
types. Nat. Genet. 43, 768–775 (2011).
23. Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a
distinct subgroup of glioma. Cancer Cell 17, 510–522 (2010).
24. Terasawa, K. et al. Epigenetic inactivation of TCF2 in ovarian cancer and various cancer
cell lines. Br. J. Cancer 94, 914–921 (2006).
25. Bailey, M. H. et al. Comprehensive Characterization of Cancer Driver Genes and
Mutations. Cell 173, 371-385.e18 (2018).
26. Zhu, H., Wang, G. & Qian, J. Transcription factors as readers and effectors of DNA
methylation. Nat. Rev. Genet. 17, 551–565 (2016).
27. Li, J. et al. Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1α
in lung cancer. Theranostics 8, 4050–4061 (2018).
28. Bergaggio, E. & Piva, R. Wild-Type IDH Enzymes as Actionable Targets for Cancer
Therapy. Cancers 11, (2019).
29. Gartside, M. G. et al. Loss-of-function fibroblast growth factor receptor-2 mutations in
melanoma. Mol. Cancer Res. 7, 41–54 (2009).
30. Yu, K., Herr, A. B., Waksman, G. & Ornitz, D. M. Loss of fibroblast growth factor receptor
2 ligand-binding specificity in Apert syndrome. Proc. Natl. Acad. Sci. U. S. A. 97, 14536–
14541 (2000).
31. Ng, P. K.-S. et al. Systematic Functional Annotation of Somatic Mutations in Cancer.
Cancer Cell 33, 450-462.e10 (2018).
98

32. Pollock, P. M. et al. Frequent activating FGFR2 mutations in endometrial carcinomas
parallel germline mutations associated with craniosynostosis and skeletal dysplasia
syndromes. Oncogene 26, 7158–7162 (2007).
33. Byron, S. A. et al. The N550K/H mutations in FGFR2 confer differential resistance to
PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia 15, 975–988
(2013).
34. Liao, R. G. et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell
carcinoma. Cancer Res. 73, 5195–5205 (2013).
35. Robertson, S. C., Tynan, J. & Donoghue, D. J. RTK mutations and human syndromes: when
good receptors turn bad. Trends Genet. 16, 368 (2000).
36. Darnell, J. E., Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2,
740–749 (2002).
37. Rani, A. & Murphy, J. J. STAT5 in Cancer and Immunity. J. Interferon Cytokine Res. 36,
226–237 (2016).
38. Garcia-Diaz, A. et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PDL2 Expression. Cell Rep. 19, 1189–1201 (2017).
39. Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev.
Immunol. 5, 375–386 (2005).
40. Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity
landscape. Genome Biol. 18, 220 (2017).
41. Yao, Z. et al. Stat5a/b are essential for normal lymphoid development and differentiation.
Proc. Natl. Acad. Sci. U. S. A. 103, 1000–1005 (2006).

99

42. Park, J.-H. et al. Signaling by intrathymic cytokines, not T cell antigen receptors, specifies
CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells. Nat.
Immunol. 11, 257–264 (2010).
43. Zhang, S. et al. Essential role of signal transducer and activator of transcription (Stat)5a but
not Stat5b for Flt3-dependent signaling. J. Exp. Med. 192, 719–728 (2000).
44. Zhang, Q., Wang, H. Y., Liu, X. & Wasik, M. A. STAT5A is epigenetically silenced by the
tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting
NPM1-ALK expression. Nat. Med. 13, 1341–1348 (2007).
45. Ferris, R. L. Immunology and Immunotherapy of Head and Neck Cancer. J. Clin. Oncol.
33, 3293–3304 (2015).
46. Villarino, A. V., Kanno, Y. & O’Shea, J. J. Mechanisms and consequences of Jak-STAT
signaling in the immune system. Nat. Immunol. 18, 374–384 (2017).
47. McInnes, L., Healy, J., Saul, N. & Großberger, L. UMAP: Uniform Manifold
Approximation and Projection. Journal of Open Source Software vol. 3 861 (2018).
48. Aster, J. C., Pear, W. S. & Blacklow, S. C. The Varied Roles of Notch in Cancer. Annu.
Rev. Pathol. 12, 245–275 (2017).
49. Pereira, B., Billaud, M. & Almeida, R. RNA-Binding Proteins in Cancer: Old Players and
New Actors. Trends Cancer Res. 3, 506–528 (2017).
50. Wauters, E. et al. DNA methylation profiling of non-small cell lung cancer reveals a
COPD-driven immune-related signature. Thorax 70, 1113–1122 (2015).
51. Hoadley, K. A. et al. Cell-of-Origin Patterns Dominate the Molecular Classification of
10,000 Tumors from 33 Types of Cancer. Cell 173, 291-304.e6 (2018).

100

52. Griffith, M. et al. CIViC is a community knowledgebase for expert crowdsourcing the
clinical interpretation of variants in cancer. Nat. Genet. 49, 170–174 (2017).
53. Shames, D. S. et al. Loss of NAPRT1 expression by tumor-specific promoter methylation
provides a novel predictive biomarker for NAMPT inhibitors. Clin. Cancer Res. 19, 6912–
6923 (2013).
54. Tsai, H.-C. et al. Transient low doses of DNA-demethylating agents exert durable antitumor
effects on hematological and epithelial tumor cells. Cancer Cell 21, 430–446 (2012).
55. Clark, D. J. et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell
Carcinoma. Cell 179, 964-983.e31 (2019).
56. Gillette, M. A. et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in
Lung Adenocarcinoma. Cell 182, 200-225.e35 (2020).
57. Dou, Y. et al. Proteogenomic Characterization of Endometrial Carcinoma. Cell 180, 729748.e26 (2020).
58. Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumornormal sample pairs. Bioinformatics 28, 1811–1817 (2012).
59. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and
heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
60. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in
cancer by exome sequencing. Genome Res. 22, 568–576 (2012).
61. Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach
to detect break points of large deletions and medium sized insertions from paired-end short
reads. Bioinformatics 25, 2865–2871 (2009).

101

62. Gao, Q. et al. Driver Fusions and Their Implications in the Development and Treatment of
Human Cancers. Cell Rep. 23, 227-238.e3 (2018).
63. Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with highthroughput sequencing data. Bioinformatics 31, 166–169 (2015).
64. Fortin, J.-P. et al. Functional normalization of 450k methylation array data improves
replication in large cancer studies. Genome Biol. 15, 503 (2014).
65. FANTOM Consortium and the RIKEN PMI and CLST (DGT) et al. A promoter-level
mammalian expression atlas. Nature 507, 462–470 (2014).
66. Mertins, P. et al. Proteogenomics connects somatic mutations to signalling in breast cancer.
Nature 534, 55–62 (2016).
67. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
68. Wilkerson, M. D. & Hayes, D. N. ConsensusClusterPlus: a class discovery tool with
confidence assessments and item tracking. Bioinformatics 26, 1572–1573 (2010).
69. Fabregat, A. et al. Reactome pathway analysis: a high-performance in-memory approach.
BMC Bioinformatics 18, 142 (2017).

102

Chapter 5: Conclusion and Future Directions
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5.1
Experimental validation can confirm and
complement large-scale multi-omic analysis.
Our work in previous chapters illustrate the power of large-scale multi-omic analysis in
understanding both heterogeneity and complexity of human cancers. We believe that our analytical
framework and systematic pan-cancer studies uncover determinants and consequences of genetic
and epigenetic variation beyond the conventional mutational profiling, revealing potential new
disease mechanisms and therapeutic opportunities. To further validate the predicted therapeutic
effect identified in our data-driven analysis results, one of the future directions that would be
interesting to pursue is to conduct wet lab experimental validation. Take the tumorigenic DNA
methylation for example, we can introduce site-directed methylation or demethylation at a
particular gene promoter in the corresponding cell line or mouse model by using CRISPR/Cas9
system1. With confirming FGFR2 upregulation after introducing site-specific demethylation at
FGFR2 promoter in endometrial cell line2, we can perform growth assay and colony formation
assay to determine the oncogenic role of hypomethylated FGFR2 in UCEC. This will help us to
elucidate the underlying mechanism of tumor development regulated by RTK hypomethylation.
Furthermore, we can apply the established cell line model in drug screening aiming to revert this
aberrant methylation in tumor cells. By harnessing the power of large-scale multi-omics analysis,
scientists can better prioritize the therapeutic candidate and devise the experimental validation
accordingly.

5.2
Combining bulk and single-cell technology can
enhance the identification of tumor origin.
Following the large-scale multi-omics bulk sequencing methods, a number of single-cell
technology that can better dissect the heterogeneous subpopulations of tumors emerged recently3.
Another future direction is to expand the depth of large-scale multi-omics analysis using single
104

cell technologies. One question we are particularly interested is to identify the cell-of-origin of
tumors, i.e. the normal cell that acquired the first cancer-promoting mutations, by leveraging the
complementary nature of high-throughput DNA methylation array and single-cell nuclei RNA
sequencing for chromatin accessibility. As part of the effort, we have done extensive work of using
methylation data to identify global methylation patterns for 6000 human tumors across 15 cancer
types from CPTAC, TCGA, and TARGET (Figure 1). By reducing methylation signals from
340,000 CGIs into two dimensions, we observed that most tumors form well-separated clusters by
the organ system, such as brain (GBM and NBL), kidney (ccRCC), blood (AML), large
intestine(COAD and READ), and uterus (UCEC), while the squamous cell cancers, i.e LSCC,
HNSCC and CESC, form a distinct cluster that partially clustered with other cancer types. The
results suggest that the projection of DNA methylation data reflects cell-of-origin faithfully. To
further dissect the particular lineage trajectories of tumors, we will use paired snATAC-seq and
snRNA-seq data for 50+ cases across 10 cancer types. First, we will reduce the snATAC-seq data
from thousands peaks into two dimensions, and identify common and distinct sub-clusters among
different groups based on the profiles of chromatin accessibility. Next, we will quantify the global
epigenetic patterns, the transcriptional network differences, and clinical relevance for those
heterogeneous sub-clusters by connecting differences in transcriptional regulation with differential
gene expression across clusters. The overall clustering for various diseases should mostly reflect
cell-of-origin faithfully, while particular sub-clusters will reveal unique lineage differentiation
trajectories. Our in-depth analysis will provide high-resolution insights to transcriptional and
cellular dynamics among tumors with common and distinct cell-of-origins.

105

5.3
High-throughput functional genomics empowers
genomics-guide cancer treatment
The current paradigm of genomic-guide cancer medicine research has been focused on
targeting single gene critical for optimal cancer cell fitness, such as oncogene or tumor suppressor
gene. However, the concerted effort of large-scale cancer multiomic profiling so far has shown
that there are finite and diminishing opportunities to cure cancer merely by targeting one single
gene4. Synthetic lethality is the genetic interaction between two or more genes where only their
co-alteration results in cell death, emerging as a promising therapeutic strategy against cancer
recently. This is exemplified by PARP inhibitor, which is an effective therapy for cancer patients
with BRCA1 or BRCA2 mutations in tumors across multiple cancer types5. When BRCA mutant
tumors are treated with a PARP inhibitor, the two complementary DNA repair pathways, DNA
homologous recombination repair and single-strand break repair, are co-targeted in tumors,
resulting in therapeutic vulnerability in tumor cells. Such synthetic lethal interactions remain to be
discovered in cancer. Therefore, the other future direction I would like to pursue is to create new
tumor vulnerability from synthetic lethal interactions among genes that lead to cancer by using
high-throughput CRISPR/Cas9-based mutagenesis studies. To take advantage of the considerable
progress in accumulated cancer sequencing data, cancer multiomics, and functional genomic assay
using CRISPR/Cas9, I propose to test the synthetic lethality interaction in a comprehensive way.
Findings will advance our understanding of the interactions among various abnormalities in
tumorigenesis, provide guidance for effective treatments based on molecular features, and
potentially help to expand the repertoire of genomics-guided therapy. My long-term goal is to
effectively identify clinical actionable targets in cancer cells by employing data-driven analysis
combined with patient-guided CRISPR mutagenesis.
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5.4

Concluding remarks

We believe that our research will have significant impact on different areas of genomicguided cancer treatment research: (1) elucidating the patterns and potential therapeutic effects of
microsatellite instability, gene fusions, and aberrant DNA methylation, (2) demonstrating how
large-scale multi-omics analysis can expand our understanding of human cancers, and (3) laying
the groundwork for how we effectively interpret tumorigenic abnormalities and associated clinical
relevance. Together, we hope that our research will bridge the bench research to the bedside
clinical application in cancer treatment.
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5.5
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Chapter 5
Figure 5.1 The cancer methylome landscape across different cancer types

Projection of the 6000 cancer methylomes using UMAP. Each point is a sample and is colored
based on the sample subtype (left), cancer type (middle), or data source (left)
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